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Abstract
The EFSA Panel on Food Additives and Flavourings (FAF) provides a scientific opinion on tartaric acid-
tartrates (E 334-337, 354) when used as food additives. The Scientific Committee for Food (SCF) in
1990 established an acceptable daily intake (ADI) of 30 mg/kg body weight (bw) per day, for L(+)-
tartaric acid and its potassium and sodium salts. The metabolism of L(+)-tartaric acid and its potassium
sodium salt was shown to be species dependent, with a greater absorption in rats than in humans. No
toxic effects, including nephrotoxicity, were observed in toxicological studies in which the L(+)-form
was tested. There was no indication for a genotoxic potential of tartaric acid and its sodium and
potassium salts. In a chronic study in rats, no indication for carcinogenicity of monosodium L(+)-
tartrate was reported at the highest dose tested (3,100 mg/kg bw per day). The available studies for
maternal or developmental toxicity did not report any relevant effects; no studies for reproductive
toxicity were available; however, no effects on reproductive organs were observed in the chronic
toxicity study. The Panel concluded that the data on systemic availability were robust enough to derive
a chemical-specific uncertainty factor instead of the usual default uncertainty factor of 100. A total
uncertainty factor of 10 was derived by applying a total interspecies uncertainty factor of 1 instead of
10, based on data showing lower internal exposure in humans compared to rats. The Panel established
a group ADI for L(+)-tartaric acid-tartrates (E 334-337 and E 354) of 240 mg/kg bw per day,
expressed as tartaric acid, by applying the total uncertainty factor of 10 to the reference point of
3,100 mg sodium tartrate/kg bw per day, approximately to 2,440 mg tartaric acid/kg bw per day. The
exposure estimates for the different population groups for the refined non-brand-loyal exposure
scenario did not exceed the group ADI of 240 mg/kg bw per day, expressed as tartaric acid. Some
recommendations were made by the Panel.
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Summary
L(+)-Tartaric acid (E 334), sodium tartrate (E 335 (i)), disodium tartrate (E 335 (ii)), potassium
tartrate (E 336 (i)), dipotassium tartrate (E 336 (ii)), potassium sodium tartrate (E 337) were
evaluated by the Joint FAO/WHO Expert Committee on Food Additives (JECFA)several times (JECFA,
1962, 1964, 1965, 1974a,b, 1975, 1977, 1978, 1983) and by the Scientific Committee for Food (SCF)
in 1990 (SCF, 1991b). Both committees established a group acceptable daily intake (ADI) of 30 mg/kg
body weight (bw) per day for L(+)-tartaric acid and its potassium and sodium salts.
Information on the manufacturing process of L(+)-tartaric acid using immobilised cells of the
bacteria Rhodococcus ruber strain CM001 or Rhodococcus sp strain USA-AN012 was submitted.
Rhodococcus ruber has not been reported to be pathogenic to humans. Since no viable cells from
Rhodococcus sp USA-AN012 remained in the final product, and the manufacturing conditions were
shown able to fully degrade DNA, the use of immobilised cells of the bacteria Rhodococcus ruber strain
CM001 or Rhodococcus sp strain USA-AN012 was not considered to pose a safety concern.
The metabolism of L(+)-tartaric acid and its potassium sodium salt was shown to be species
dependent. In rats, after oral administration, up to 81% of labelled tartrate was absorbed. In rats, L(+)
and D(-)-tartrate were excreted differently in urine after gavage, the L(+)-form being more efficiently
excreted than the D(-)-form. Up to 10% of labelled parenteral tartrate was expired as CO2 within 6 h
and 63% was found in the urine over 24 h, which indicated significant metabolism by tissues. High
rate of renal excretion (up to 60% within 12 h) was reported in dogs receiving tartaric acid. After
parenteral injection of tartrate, recovery ranged from 70% in rabbits, dogs and rats to almost 100% in
guinea pigs. Therefore, tissue metabolism could not be excluded in these species; however, it played a
minor role in disposal of tartrate.
In humans, only 12% of tartrate administered orally appeared in the urine; as this was unrelated to
dose, the Panel considered this as passive absorption. The difference in urinary excretion after an oral
dose (12%) or an intravenous dose (66%) suggested that only a fraction of the oral dose was
systemically available. A 91% of an intramuscular dose of unlabelled tartrate was recovered in urine,
which according to the authors, indicated that the human body cannot metabolise tartrate. After an
intravenous injection of 14C-L-tartrate, it has been reported that 66% of radioactivity was excreted in
the urine in 22 h, and that 18% was excreted as 14CO2 over 8 h. The concentration of
14CO2 in
expired air peaked after 1 h and contained 7% of the dose, suggesting rapid metabolism by tissue
enzymes. The Panel considered that the different recoveries of 91 and 66% may be due to the
different stereospecific forms used. However, these recoveries are not directly comparable because
radioactivity was measured in one study while unlabelled tartrate was analysed in the other study.
Tartrate was fermented by colonic bacteria, with L(+)-tartrate being metabolised faster than D(-)-
tartrate. Tartaric acid/tartrate were fermented by colonic bacteria to Short Chain Fatty Acids (SCFA),
which then can be absorbed in the colon.
It is necessary to consider whether the hazard could only be due to the parent compounds. In this
respect, the metabolic products originating from the metabolism of the unabsorbed tartaric acid/tartrate
by the microbiome in the lower part of the gastrointestinal tract have to be evaluated. It was confirmed
that tartrate is not metabolised to oxalate, a potential metabolite with toxic properties for the kidney;
most of the 14C- label was recovered as 14CO2. Hence, from the absorption, distribution, metabolism,
excretion (ADME) data, it can be concluded that the metabolites would not cause potential side effects.
A LD10 value for disodium tartrate above 4,000 mg/kg bw in mice was indicative of a low oral
toxicity of tartrate in this species. In outdated studies, acute renal toxicity was seen in rabbits and
dogs after a single oral dose of tartaric acid or Rochelle salt (potassium sodium tartrate) from 26.6 and
600 mg/kg bw (expressed as tartaric acid), respectively. In these studies, the stereoisomeric
composition of the studied material was not specified. The species differences between rats, rabbits
and dogs in terms of renal toxicity reflected probably the species differences in the absorption of
tartaric acid and tartrates.
No adverse effects were observed in rats given 2,730 monosodium L-tartrate/kg bw per day. In the
same study, DL-tartaric acid was shown to cause kidney effects. Furthermore, in a 90-day study in rats,
a no observed adverse effect level (NOAEL) of 60 mg/kg bw per day was identified for monopotassium
DL-tartrate, based on kidney histological alterations (obstructive nephropathy) reported at higher doses.
In rabbits given 550 mg monosodium tartrate/kg bw per day acid (stereoisomeric composition not
specified), no adverse effects were observed. Advanced tubular degeneration of the kidneys and
increased blood non-protein nitrogen (NPN), creatinine and albumin were observed in one out of the
four dogs given 990 mg/kg bw per day tartaric acid (stereoisomeric composition not specified), the
Re-evaluation of tartaric acid-tartrates (E 334-337, 354)
www.efsa.europa.eu/efsajournal 3 EFSA Journal 2020;18(3):6030
only dose tested. The Panel considered that the renal effects reported with tartrates were most likely
due to the presence of the D(-)-form of tartaric acid.
The Panel considered that there was no concern for genotoxicity for tartaric acid and its sodium
and potassium salts.
A dosage-related reduction of body weight and higher relative weights for a number of organs were
reported for rats fed monosodium tartrate at doses equal to or above 1,620 and 2,050 mg/kg bw per
day for males and females, respectively, for 2 years. These increased relative organ weights were
mainly due to decreased body weights. The Panel considered that the decrease in body weights was
due to a nutritional imbalance likely due to palatability effect, and therefore, considered these
increased relative organ weights not of toxicological significance. Histopathological examination did not
reveal a difference between treated animals and controls. From the available chronic and
carcinogenicity studies, the Panel considered that monosodium L(+)-tartrate was not carcinogenic and
identified an NOAEL of 3,100 mg monosodium tartrate/kg bw per day, the highest dose tested.
No maternal or developmental effects were reported at the highest dose tested (mice: 274 mg/kg
bw per day, rats: 181 mg/kg bw per day, hamsters: 225 mg/kg bw per day or rabbits: 215 mg/kg bw
per day for 13 days). No studies for reproductive toxicity were available; however, from the available
chronic studies, there was no indication of a possible effect on reproductive organs at the doses
tested.
Some publications reported that excessive consumption of tartaric acid by humans induced some
effects. Daily doses of 10 g sodium tartrate caused nausea, vomiting and abdominal cramps in a
minority of patients (< 2.1%) with pre-existing health problems. Four cases of acute tubular necrosis
in patients who had consumed ‘large amounts of tartaric acid’; the form of tartaric acid absorbed was
not specified. The Panel noted that adverse effects of tartrate or tartaric acid were observed only at
high oral intakes and, the form of tartaric acid consumed was not indicated. Therefore, although being
indicative of an acute toxicity in humans, and given the difference in toxicity between the D(-)- and L
(+)-forms, these effects were considered not relevant for the purpose of evaluating L(+)-tartaric acid
and tartrates as food additives.
A group ADI of 30 mg/kg bw per day was established by JECFA in 1974 and later endorsed by the
SCF in 1991. This ADI was derived from an NOAEL of 3,000 mg monosodium tartrate/kg bw per day,
the highest dose tested in a chronic toxicity study in rats and applying an uncertainty factor of 100.
The Panel considered whether this uncertainty factor would be appropriate given the fact that the
absorption of tartaric acid/tartrate is greater in rats than humans. Whereas in the rat the systemic
availability was 81%, the systemic availability in humans amounted to 18%.
The Panel decided that the available data on systemic availability were robust enough to derive a
chemical-specific adjustment factor instead of the usual default uncertainty factor of 100.
The default uncertainty factor of 100 is composed of a factor of 10 accounting for the difference
between animal and human and a second factor of 10 accounting for the variability in the human
population. In 2004, the IPCS/WHO proposed a framework indicating how chemical-specific
toxicokinetic and/or toxicodynamic data can be used to replace the default factors or its subfactors.
When considering the systemic toxicity of the parent compounds tartaric acid/tartrates, toxicity is
related to the amount, which is given as the internal dose. Accordingly, the external (administrated)
dose can be adjusted to the internal dose by taking into account how much is absorbed and
systemically available after oral administration. In humans, 18% of the dose is systemically available
whereas in rats, the figure is 81%. Furthermore, it is to be noted that the rate of metabolism is similar
between rats and humans as measured by the rate of expired CO2. The usual default value for the
toxicokinetic differences between rats and humans is 4 assuming that in general the internal human
exposure is four times higher than in the rat with the same external dose. In case of tartrate, the
situation is reverse; in humans the internal exposure is 22% of that in rats. Hence, when considering
the different absorption in rats and humans, together with the similar rate of metabolism, the
interspecies toxicokinetic factor may be reduced to 0.22 instead of 4.
Multiplying this interspecies toxicokinetic factor of 0.22 by the default toxicodynamic factor of 2.5
would result in a total interspecies uncertainty factor of 0.55. As a conservative approach, the
Panel decided to use an interspecies factor of 1. For the intraspecies factor, the Panel had no
information regarding possible modification of this default factor and, therefore, the default factor of
10 was used. Accordingly, the resulting overall uncertainty factor used was 10 (1 9 10).
Applying the total uncertainty factor of 10 to the reference point of 3,100 mg sodium tartrate/kg
bw per day (the highest dose tested), that is approximately 2,400 mg tartaric acid/kg bw per day, will
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result in a group ADI for tartaric acid and tartrates (E 334-337 and E 354) of 240 mg/kg bw per day
expressed as tartaric acid.
The difference between the ADI established by the SCF and the one derived in this opinion is due
to the application of a chemical specific interspecies uncertainty factor instead of the default
uncertainty factor used in previous evaluations.
Dietary to tartaric acid and tartrates (E 334-337 and E 354) from their use as food additives was
calculated according to different exposure scenarios based on maximum permitted levels and the
reported use levels, as described in Section 3.4. According to Annex II to Regulation N°1333/2008,
tartaric acid and tartrates (E 334-337 and E 354) are authorised in 81 food categories of which 66
under Group I food additives.
Use levels were reported by industry for 17 food categories. Based on the information of the
Mintel’s GNPD, approximately 82% of the food products labelled with tartaric acid and tartrates
(E 334-337 and E 354) in this database were considered in the exposure assessment. Together with
the observation that the Panel assumed that 100% of the foods belonging to a food category included
in the assessment contained the food additives, whereas the average percentage was 1% according to
the Mintel’s GNPD, and that the possible degradation of tartaric acid at high temperatures was not
considered in the assessment, the Panel considered that the exposure to tartaric acid and tartrates
(E 334-337 and E 354) from their use as food additives according to Annex II to Regulation (EC)
No 1333/2008 was overestimated in all exposure scenarios.
Tartaric acid and tartrates (E 334-337 and E 354) are used as ‘acidity regulator’ and are therefore
not expected to change the organoleptic properties of the final food at the concentration used as a
food additive. Therefore, the Panel considered the non-brand-loyal scenario covering the general
population as most appropriate for risk characterisation. Dietary exposure to tartaric acid and tartrates
(E 334-337 and E 354) according to this exposure scenario was up to 91 mg/kg bw per day at the
mean level and 174 mg/kg bw per day at the high (P95) level, both in infants. This exposure did not
exceed the group ADI of 240 mg/kg bw per day, expressed as tartaric acid.
Since tartaric acid also occurs naturally in food, the Panel calculated the intake of tartaric acid from
natural sources (non-processed fruits and vegetables and wine), based on the limited available
information reported in the literature. This exposure was lower than the calculated exposure from the
use of tartaric acid-tartrates as food additives, maximally 26 mg/kg bw per day in the elderly.
Exposure to tartaric acid, in addition to natural occurrence, can also occur by release from other
food additives, including tartaric acid esters of mono- and diglycerides of fatty acids (E 472d), mono-
and diacetyl tartaric acid esters of mono- and diglycerides of fatty acids (E 472e), mixed acetic and
tartaric acid esters of mono- and diglycerides of fatty acids (E 472f), metatartaric acid (E 353) and
stearyl tartrate (E 483). The Panel, therefore, also calculated the potential exposure to tartaric acid
from these sources and combined it with the exposure to tartaric acid due to the use of tartaric acid
and tartrates (E 334-337 and E 354). The non-brand loyal exposure scenario was considered for the
exposure due to the use of food additives. The exposure to tartaric acid from stearyl tartrate (E 483)
was not included in this assessment, as no reported use levels were available for this food additive.
The highest P95 level of exposure was estimated for toddlers at 285 mg/kg bw per day. However, the
Panel did not consider this exceedance to indicate a possible health concern, due to the overestimation
of the exposure.
The Panel made some recommendations to be considered for possible revision of the EU
specifications of these food additives
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1. Introduction
The present opinion document deals with the re-evaluation of L(+)-tartaric acid (E 334),
monosodium tartrate (E 335 (i)), disodium tartrate (E 335 (ii)), monopotassium tartrate (E 336 (i)),
dipotassium tartrate (E 336 (ii)), potassium sodium tartrate (E 337) and calcium tartrate (E 354) when
used as food additives.
1.1. Background and Terms of Reference as provided by the European
Commission
1.1.1. Background
Regulation (EC) No 1333/20081 of the European Parliament and of the Council on food additives
requires that food additives are subject to a safety evaluation by the European Food Safety Authority
(EFSA) before they are permitted for use in the European Union. In addition, it is foreseen that food
additives must be kept under continuous observation and must be re-evaluated by EFSA.
For this purpose, a programme for the re-evaluation of food additives that were already permitted in
the European Union before 20 January 2009 has been set up under the Regulation (EU) No 257/20102.
This Regulation also foresees that food additives are re-evaluated whenever necessary in light of
changing conditions of use and new scientific information. For efficiency and practical purposes, the re-
evaluation should, as far as possible, be conducted by group of food additives according to the main
functional class to which they belong.
The order of priorities for the re-evaluation of the currently approved food additives should be set
on the basis of the following criteria: the time since the last evaluation of a food additive by the
Scientific Committee on Food (SCF) or by EFSA, the availability of new scientific evidence, the extent
of use of a food additive in food and the human exposure to the food additive taking also into account
the outcome of the Report from the Commission on Dietary Food Additive Intake in the EU3 of 2001.
The report “Food additives in Europe 20004” submitted by the Nordic Council of Ministers to the
Commission, provides additional information for the prioritisation of additives for re-evaluation. As
colours were among the first additives to be evaluated, these food additives should be re-evaluated
with a highest priority.
In 2003, the Commission already requested EFSA to start a systematic re-evaluation of authorised
food additives. However, as a result of adoption of Regulation (EU) 257/2010 the 2003 Terms of
References are replaced by those below.
1.1.2. Terms of Reference
The Commission asks the European Food Safety Authority to re-evaluate the safety of food
additives already permitted in the Union before 2009 and to issue scientific opinions on these
additives, taking especially into account the priorities, procedures and deadlines that are enshrined in
the Regulation (EU) No 257/2010 of 25 march 2010 setting up a programme for the re-evaluation of
approved food additives in accordance with the Regulation (EC) No 1333/2008 of the European
Parliament and of the Council on food additives.
1.2. Information on existing authorisations and evaluations
L(+)-Tartaric acid (E 334), sodium tartrates (E 335), potassium tartrates (E 336), sodium potassium
tartrate (E 337) and calcium tartrate (E 354) are authorised as food additives according to Regulation
(EC) No 1333/2008 on food additives. Specific purity criteria have been defined in the Commission
Regulation (EU) No 231/20125 for L(+)-tartaric acid (E 334), monosodium tartrate (E 335(i)), disodium
1 Regulation (EC) No 1333/2008 of the European Parliament and of the Council of 16 December 2008 on food additives. OJ L
354, 31.12.2008.
2 Commission Regulation (EU) No 257/2010 of 25 march 2010 setting up a programme for the re-evaluation of approved food
additives in accordance with Regulation (EC) No 1333/2008 of the European Parliament and of the Council on food additives.
OJ L 80, 26.3.2010, p. 19–27.
3 COM(2001) 542 final.
4 Food Additives in Europe 2000, Status of safety assessments of food additives presently permitted in the EU, Nordic Council of
Ministers, TemaNord (Nordic Council of Ministers), 2002, 560.
5 Commission Regulation (EU) No 231/2012 of 9 march 2012 laying down specifications for food additives listed in Annexes II
and III to Regulation (EC) no 1333/2008 of the European Parliament and of the Council. OJ L 83, 22.3.2012, p 1.
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tartrate (E 335(ii)), monopotassium tartrate (E 336(i)), dipotassium tartrate (E 336(ii)), potassium
sodium tartrate (E 337) and calcium tartrate (E 354).
L(+)-Tartaric acid (E 334) is authorised to be used as a food additive (acidity regulator) in wine
according to Regulation (EC) No 934/20196. Dipotassium tartrate, monopotassium tartrate and calcium
tartrate are authorised to be used as processing aids in wine according to Regulation (EC) No 934/
2019.
L(+)-Tartaric acid (E 334) and its sodium and potassium salts (E 335, E 336,E 337), used as food
additives, have previously been evaluated by the SCF in 1978, 1990 and 1992 (SCF, 1978, 1991a,b,
1994). Although not being actually evaluated, calcium tartrate was considered acceptable in weaning
foods (SCF, 1994).
In 1978, the SCF stated that L(+)-tartaric acid and its sodium and potassium salts were acceptable
for use in fine bakery wares (SCF, 1978). No detailed evaluation was performed, but it was stated that
the Committee accepted, on a provisional basis, the ADI established by JECFA (1,800 mg/adult per
day as total L(+)-tartaric acid from all sources, equal to 30 mg tartaric acid/kg bw for a 60 kg person).
In 1990, the SCF found L(+)-tartaric acid, sodium L(+)-tartrate and potassium L(+)-tartrate
acceptable for use in weaning foods as raising agents in biscuits and rusks with a residue level of not
more than 0.5 g/100 g (SCF, 1991a). In 1992, calcium L(+)-tartrate was also listed as acceptable in
weaning foods with the same restriction (SCF, 1994).
In 1990, the SCF (SCF, 1991b) endorsed the group ADI of 30 mg/kg bw established previously by
JECFA (1974a). The SCF report stated the following: ‘the long-term study in rats with L(+)-tartrate
showed no adverse effects at the highest level tested. Tartrates have been used medicinally for long
periods. The evaluation of L(+)-tartrate can therefore be based on experimental data, the metabolic
inertness of tartrates and the fact that they are normal constituents of food. Monosodium-L(+)-tartrate
also produced no adverse effects in long-term studies. The available data were inadequate to assess
the safety of DL-tartrate. The Committee agrees with the ADI of 30 mg/kg body weight established by
JECFA for L(+) tartrate, while the DL-form is not acceptable.’
L(+)-Tartaric acid and its sodium, potassium and sodium-potassium salts have been evaluated by JECFA
in 1961, 1963, 1964, 1973, 1975 and 1977 (JECFA, 1962, 1964, 1965, 1974a,b, 1975, 1977, 1978).
In 1973, the JECFA established an acceptable daily intake (ADI) of 0–30 mg/kg bw (expressed as L
(+)-Tartaric acid) for L(+)-tartaric acid and its potassium, potassium sodium and sodium salts (JECFA,
1974a).
In 1978, the JECFA evaluated tartaric acid and monosodium L(+)-tartrate and, on the ground of a
new long-term study in rat, reconfirmed an ADI for L(+)-tartrate monosodium at 0–30 mg/kg bw
expressed as tartaric acid.
In 2017, during the evaluation of metatartaric acid, JECFA reviewed two genotoxicity studies
(Ishidate et al. (1984) and Hayashi et al. (1988)) and the publication (Hunter et al., 1977) of the
unpublished report that was used to establish the ADI of L(+)-tartaric acid at its latest evaluation
(1977). JECFA concluded that the body of evidence suggests no change to the group ADI previously
established for L(+)-tartaric acid and its sodium, potassium and potassium–sodium salts, expressed as
L(+)-tartaric acid (JECFA, 2017).
L(+)-Tartaric acid and its sodium, potassium and calcium salts were evaluated by the Nordic Council
of Ministers in 2000 (TemaNord, 2002). A re-evaluation was not recommended provided that the
exposure was below the ADI
EFSA evaluated the safety of the complexation product of sodium tartrates and iron(III) (FemTA)
when used as a food additive (EFSA ANS Panel, 2015). FemTA is a mixture of sodium tartrates [DL-and
meso-tartrates] with iron(III) chloride; where meso-tartrate represents approximately 65% of the total
tartrate content. The ANS Panel concluded that the toxicity database was insufficient to establish an
ADI for FemTA; however, considering the calculated MoS, it was also concluded that there is no safety
concern for the use of FemTA only in salt and its substitutes, with a use level of 106 mg FemTA/kg salt
as an anti-caking agent. Following this assessment, the food additive iron tartrate (E534) has been
included in Annex II of Regulation (EC) No 1333/2008.
‘L-carnitine-L-tartrate’ is authorised to be added to food in the following food categories according
to Regulation (EU) No 609/2013: Infant formula and follow on formula, food for special medical
6 Commission Delegated Regulation (EU) 2019/934 of 12 march 2019 supplementing Regulation (EU) No 1308/2013 of the
European Parliament and of the Council as regards wine-growing areas where the alcoholic strength may be increased,
authorised oenological practices and restrictions applicable to the production and conservation of grapevine products, the
minimum percentage of alcohol for by-products and their disposal, and publication of OIV files. OJ L 149, 7.6.2019, p. 1–52
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purposes and total diet replacement for weight control. ‘Choline bitartrate’ (stereoisomeric composition
of tartrate not specified) is also authorised to be used in the same food categories in addition to
processed cereal-based food and baby food (Regulation (EU) No 609/2013).
Tartaric acid (FL 08.018) is a flavouring substance included in the Union list of flavourings
(Commission Implementing Regulation (EU) No 872/2012).
L(+)-Tartaric acid and potassium sodium tartrate have been registered under the REACH Regulation
1907/20067 (ECHA, online).
L(+)-Tartaric acid (PM Ref. 92160) is included in the Union list of authorised substances that may be
intentionally used in the manufacture of plastic materials which are intended to come into contact with
food (Annex I to Commission Regulation (EU) No 10/20118). Furthermore, L(+)-tartaric acid, disodium
tartrate, dipotassium tartrate and potassium sodium tartrate are permitted as buffering substances in
cosmetic products. Calcium tartrate is permitted as skin conditioner in cosmetic products (European
Commission database-CosIng9).
2. Data and methodologies
Data
The FAF Panel was not provided with a newly submitted dossier. EFSA launched public call for
data10,11,12 to collect information from interested parties.
The Panel based its assessment on information submitted to EFSA following the public calls for
data, information from previous evaluations and additional available literature up to January 2020.
Attempts were made at retrieving relevant original study reports on which previous evaluations or
reviews were based; however, these were not always available to the Panel.
Food consumption data used to estimate the dietary exposure to tartaric acid-tartrates (E 334-337,
354) were derived from the EFSA Comprehensive European Food Consumption Database
(Comprehensive Database13).
The Mintel’s Global New Products Database (GNPD) was used to verify the use of tartaric acid-
tartrates (E 334-337, 354) in food and beverage products and food supplements within the EU’s food
market. The Mintel’s GNPD is an online database that contains the compulsory ingredient information
present on the label of numerous products.
Methodologies
This opinion was formulated following the principles described in the EFSA Guidance on
transparency with regard to scientific aspects of risk assessment (EFSA Scientific Committee, 2009)
and following the relevant existing guidance documents from the EFSA Scientific Committee.
The FAF Panel assessed the safety of L(+)-tartaric acid (E 334), monosodium tartrate (E 335 (i)),
disodium tartrate (E 335 (ii)), monopotassium tartrate (E 336 (i)), dipotassium tartrate (E 336 (ii)),
potassium sodium tartrate (E 337) and calcium tartrate (E 354) as food additives in line with the
principles laid down in Regulation (EU) 257/2010 and in the relevant guidance documents: Guidance
on submission for food additive evaluations by the SCF (2001) and taking into consideration the
Guidance for submission for food additive evaluations in 2012 (EFSA ANS Panel, 2012).
When in animal studies, the test substance was administered in the feed or in drinking water, but
doses were not explicitly reported by the authors as mg/kg bw per day based on actual feed or water
consumption, the daily intake is calculated by the Panel using the relevant default values. In case of
rodents, the values as indicated in the EFSA Scientific Committee Guidance document (EFSA Scientific
7 Regulation (EC) No 1907/2006 of the European Parliament and of the Council of 18 December 2006 concerning the
Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH). OJ L 396, 30.12.2006.
8 Commission Regulation (EU) No 10/2011 of 14 January 2011 on plastic materials and articles intended to come into contact
with food. OJ L 12, 15.1.2011, p. 1–89.
9 Available online: http://ec.europa.eu/consumers/cosmetics/cosing/index.cfm?fuseaction=search.simple
10 Call for scientific data on miscellaneous food additives permitted in the EU and belonging to several functional classes.
Published: 8 June 2010. Available from: http://www.efsa.europa.eu/en/dataclosed/call/ans100609
11 Call for scientific data on L(+)-tartaric acid (E 334) and related food additives authorised in the EU. Published: 31 may 2016.
Available from: https://www.efsa.europa.eu/sites/default/files/consultation/160531.pdf
12 Call for food additives usage level and/or concentration data in food and beverages intended for human consumption (Batch
5). Available from: https://www.efsa.europa.eu/sites/default/files/consultation/160524.pdf
13 Available online: http://www.efsa.europa.eu/en/datexfoodcdb/datexfooddb.htm
Re-evaluation of tartaric acid-tartrates (E 334-337, 354)
www.efsa.europa.eu/efsajournal 10 EFSA Journal 2020;18(3):6030
Committee, 2012) are applied. In the case of other animal species, the default values by JECFA (2000)
are used. In these cases, the dose was expressed as ‘equivalent to mg/kg bw per day’.
When relevant, the dose of the test substance as a salt of tartaric acid was calculated in mg of
tartaric acid on the basis of the molecular weight of the corresponding salt of tartaric acid as indicated
in the Regulation (EU) No 231/2012.
Dietary exposure to tartaric acid and tartrates (E 334-337 and E 354) from their use as food
additives was estimated combining the food consumption data available within the EFSA
Comprehensive Database with the maximum permitted levels and/or reported use levels submitted to
EFSA following two calls for data. The exposure was estimated according to different exposure
scenarios (see Section 3.4). Uncertainties in the exposure assessment were identified and discussed.
3. Assessment
3.1. Technical data
3.1.1. Identity of the substances
L(+)-Tartaric acid (E 334)
According to Commission Regulation (EU) No 231/2012 L(+), tartaric acid (E 334) has the chemical
formula C4H6O6; it is identified and defined as:
Chemical names: L-tartaric acid; L-2,3-dihydroxybutanedioic acid; d-a,b-dihydroxy-succinic acid.
EINECS number: 201-766-0
Molecular weight: 150.09 g/mol
Description: colourless or translucent crystalline solid or white crystalline powder
Melting range: 168–170°C
Specific rotation: [a]D
20 between + 11.5° and + 13.5° (20% w/v aqueous solution).
According to JECFA specifications on solubility, L(+)-tartaric acid is very soluble in water and freely
soluble in ethanol (JECFA, 2006).
The corresponding CAS number is 87-69-4; the melting point is 169°C (SRC), the boiling point is
95–97°C, the pKa Value (predicted): 3.07  0.34 (SciFinder14, software). Structural formula is
presented in Figure 1.
Synonyms (SciFinder, software): (2R,3R)-2,3-dihydroxybutanedioic acid, butanedioic acid, 2,3-
dihydroxy- [R-(R*,R*)]-; (+)-(2R,3R)-L(+)-tartaric acid; (+)-(R,R)-tartaric acid; (+)-tartaric acid;
(2R,3R)-(+)- tartaric acid; (2R,3R)-2,3-Dihydroxysuccinic acid; (2R,3R)- tartaric acid; (R,R)-(+)- tartaric
acid; (R,R)- tartaric acid; tartaric acid (+L).
Monosodium tartrate (E 335(i))
According to Commission Regulation (EU) No 231/2012, monosodium tartrate (E 335(i)) is
identified and defined as:
Synonyms: Monosodium salt of L(+)-tartaric acid
Chemical names: monosodium salt of L(+)-tartaric acid; monosodium salt of L-2,3-
dihydroxybutanedioic acid; monohydrated monosodium salt of L(+)-tartaric
acid
Chemical formula: C4H5O6NaH2O
Molecular weight: 194.05 g/mol
Description: transparent colourless crystals
Figure 1: Structural formula of L(+) tartaric acid
14 SciFinder® the choice for chemistry researchTM.
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The Panel noted that the molecular weight listed in Commission Regulation (EU) No 231/2012 is
erroneous and should be corrected to ‘190.08 g/mol’.
The CAS Registry Number for monosodium L(+)-tartaric acid monohydrate is 6131-98-2 (SciFinder,
software). No information on EC (EINECS) number. The structural formula for the anhydrous form is
presented in Figure 2.
Synonyms: sodium bitartrate monohydrate; butanedioic acid, 2,3-dihydroxy-(2R,3R)-, monosodium
salt, monohydrate (1:1:1); butanedioic acid, 2,3-dihydroxy- (2R,3R)-, monosodium salt, monohydrate
(9CI); sodium hydrogen (+)-tartrate monohydrate (SciFinder, software).
Disodium tartrate (E 335(ii))
According to Commission Regulation (EU) No 231/2012, disodium tartrate (E 335(ii)) is identified
and defined as:
Chemical names: disodium L-tartrate; disodium (+)-tartrate; disodium salt of (+)-2,3-
dihydroxybutanedioic acid; dihydrated disodium salt of L(+)- tartaric acid
Chemical formula: C4H4O6Na22H2O
Molecular weight: 230.8 g/mol
EINECS Number: 212-773-3
Description: transparent colourless crystals
Solubility: 1 g is insoluble in 3 mL of water. Insoluble in ethanol
The Panel noted that the EINECS Number cited in Commission Regulation 231/2012 corresponds to
the anhydrous form, while the authorised form is the dihydrate.
The Panel noted that in the description of solubility in water in the EU specification for disodium
tartrate (E 335(ii)), the term ‘insoluble’ is incorrect and should be replaced by ‘soluble’.
According to available information, the solubility in water for disodium L(+)-tartrate dihydrate is
290 g/L (20°C) (Sigmaldrich catalogue online15).
CAS Registry Number for disodium L(+)-tartaric acid dihydrate is 6106-24-7 (SciFinder, software); no
EC/EINECS Number assigned to this CAS Number. The structural formula for the anhydrous form (CAS
Number 868-18-8) is presented in Figure 3.
Synonyms: butanedioic acid, 2,3-dihydroxy- (2R, 3R)-, disodium salt, dihydrate (9CI); butanedioic
acid, 2,3-dihydroxy-[R-(R*,R*)]-, disodium salt, dihydrate (SciFinder, software). In the JECFA
specification for sodium L(+)-tartrate (INS No 335), sodium dextro-tartrate is mentioned as a synonym
(JECFA, 2009).
Monopotassium tartrate (E 336 (i))
According to Commission Regulation (EU) No 231/2012, monopotassium tartrate (E 336(i)) is
identified and defined as:
Synonyms: Monobasic potassium tartrate
Chemical names: Anhydrous monopotassium salt of L(+)-tartaric acid; Monopotassium salt of
L-2,3-dihydroxybutanedioic acid
Chemical formula: C4H5O6K
Figure 2: Structural formula of monosodium tartrate (anhydrous form)
Figure 3: Structural formula of disodium tartrate (anhydrous form)
15 https://www.sigmaaldrich.com/catalog/product/mm/106664?lang=it&region=IT
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Molecular weight: 188.17 g/mol
Description: white crystalline or granulated powder
Melting point: 230°C
The CAS Registry Number for monopotassium L-(+)-tartaric acid is 868-14-4 (SciFinder, software).
The EC Number assigned for this CAS Number is 212-769-1 (EC inventory, online); however, no
indication of the stereochemistry is given in the EC inventory.
According to Kherici et al. (2015), the solubility of monopotassium tartrate in water is 5.78 g/L in
20°C. The structural formula is presented in Figure 4.
Synonyms: butanedioic acid, 2,3-dihydroxy-(2R,3R)-, monopotassium salt (9CI); L(+)-tartaric acid,
monopotassium salt (8CI); potassium hydrogen L(+)-tartrate (SciFinder, software).
Dipotassium tartrate (E 336(ii))
According to Commission Regulation (EU) No 231/2012, dipotassium tartrate (E 336(ii)) is identified
and defined as:
Synonyms: dibasic potassium tartrate
Chemical names: dipotassium salt of L-2,3-dihydroxybutanedioic acid; Dipotassium salt with
half a molecule of water of L(+)-tartaric acid
EINECS Number: 213-067-8
Chemical formula: C4H4O6K2½H2O
Molecular weight: 235.2 g/mol
Description: white crystalline or granulated powder
The Panel noted that the EINECS Number cited in Commission Regulation (EU) No 231/2012
corresponds to the anhydrous form, while the authorised form is the hemihydrate.
The CAS Registry Number for dipotassium L(+)-tartaric acid hemihydrate is 6100-19-2. The
structural formula for the anhydrous form is presented in Figure 5.
Synonyms (SciFinder, software): butanedioic acid, 2,3-dihydroxy-(2R,3R)-, dipotassium salt, hydrate
(2:1); dipotassium tartrate hemihydrate.
Potassium sodium tartrate (E 337)
According to Commission Regulation (EU) No 231/2012, potassium sodium tartrate (E 337) is
identified and defined as:
Synonyms: potassium sodium L(+)-tartrate; Rochelle salt; Seignette salt




Molecular weight: 282.23 g/mol
Description: colourless crystals or white crystalline powder
Solubility: 1 g in 1 mL water; insoluble in ethanol
Melting point range: 70–80°C
Figure 4: Structural formula of monopotassium tartrate
Figure 5: Structural formula of dipotassium tartrate (anhydrous form)
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The Panel noted that the EINECS Number cited in Commission Regulation (EU) No 231/2012
corresponds to the anhydrous form, while the tetrahydrate is the authorised form. The CAS Registry
number for potassium sodium L(+)-tartrate tetrahydrate is 6381-59-5 (SciFinder, software). The
structural formula for the anhydrous form is presented in Figure 6.
Synonyms: butanedioic acid, 2,3-dihydroxy- (2R,3R-), monopotassium monosodium salt,
tetrahydrate (9CI); tartaric acid, monopotassium monosodium salt, tetrahydrate, L(+)-(8CI) (SciFinder,
software).
The Panel also noted that the chemical names and the synonyms listed in Commission Regulation
(EU) No 231/2012 relate to the anhydrous form and may lead to misinterpretations of the authorised
forms of the food additive.
Calcium tartrate (E 354)
According to Commission Regulation (EU) No 231/2012, calcium tartrate (E 354) is identified and
defined as:
Synonym: L-calcium tartrate
Chemical name: calcium L(+)-2,3-dihydroxybutanedioate di-hydrate
Chemical formula: C4H4CaO62H2O
Molecular weight: 224.18 g/mol
Description: fine crystalline powder with a white or off-white colour
Solubility: slightly soluble in water, sparingly soluble in ethanol, slightly soluble in diethyl
ether and soluble in acids
Specific rotation: [a]D
20 +7.0° to + 7.4° (0.1% in a 1N HCl solution)
No information on the CAS Registry Number and the EC (EINECS) Number are available for calcium
L(+)-tartrate dihydrate. The structural formula for the anhydrous form is presented in Figure 7.
3.1.2. Specifications
Commission Regulation (EU) No 231/2012 on specifications for food additives lays down
specifications for L(+)-tartaric acid (E 334), monosodium tartrate (E 335(i)), disodium tartrate (E 335
(ii)), monopotassium tartrate (E 336(i)), dipotassium tartrate (E 336(ii)), potassium sodium tartrate
(E 337) and calcium tartrate (E 354) used as food additives (see Tables 1–7). JECFA has prepared
specifications for L(+)-tartaric acid, disodium L(+)-tartrate and potassium sodium L(+)-tartrate (JECFA,
2006, 2009).
Figure 6: Structural formula of potassium sodium tartrate (anhydrous form)
Figure 7: Structural formula of calcium tartrate (anhydrous form)
Table 1: Specifications for L(+)-tartaric acid (E 334) according to Commission Regulation (EU) No
231/2012 and JECFA (2006)
Commission Regulation (EU) No 231/2012 JECFA (2006)
Assay Content not less than 99.5% on the anhydrous
basis
Not less than 99.5% on the dried basis
Description Colourless or translucent crystalline solid or white
crystalline powder
Colourless or translucent crystals, or white,
fine to granular, crystalline powder;
odourless
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Commission Regulation (EU) No 231/2012 JECFA (2006)
Identification
Melting range Between 168°C and 170°C –
Test for tartrate Passes test Passes test
Specific rotation [a]D
20 between + 11.5° and + 13.5° (20% w/v
aqueous solution)
[alfa] 20, D: Between + 11.5° and + 13.5°.
A 1 in 10 solution is dextrorotatory
Solubility – Very soluble in water; freely soluble in
ethanol
Purity
Loss on drying Not more than 0.5% (over P2O5, 3 h) Not more than 0.5% (over P2O5, 3 h)
Sulfated ash Not more than 1,000 mg/kg (after calcination at
800  25°C)
Not more than 0.1%
Lead Not more than 2 mg/kg Not more than 2 mg/kg
Mercury Not more than 1 mg/kg –
Oxalates Not more than 100 mg/kg expressed as oxalic
acid, after drying
[Test]
Sulfates – Not more than 0.05%
Table 2: Specifications for monosodium tartrate (E 335 (i)) according to Commission Regulation
(EU) No 231/2012
Commission Regulation (EU) 231/2012
Assay Content not less than 99% on the anhydrous basis
Description Transparent colourless crystals
Identification
Test for tartrate Passes test
Test for sodium Passes test
Purity
Loss on drying Not more than 10.0% (105°C, 4 h)
Oxalates Not more than 100 mg/kg (expressed as oxalic acid, after drying)
Arsenic Not more than 3 mg/kg
Lead Not more than 2 mg/kg
Mercury Not more than 1 mg/kg
Table 3: Specifications for disodium tartrate (E 335 (ii)) according to Commission Regulation (EU)
No 231/2012 and JECFA (JECFA, 2009)
Commission Regulation 231/2012 JECFA (2009)
Assay Content not less than 99% on the anhydrous basis Not less than 99% after drying
Description Transparent, colourless crystals Transparent, colourless and odourless
crystals
Identification
Test for tartrate Passes test Passes test
Test for sodium Passes test Passes test
Solubility 1 g is insoluble in 3 mL of water. Insoluble in
ethanol
1 g is soluble in 3 mL of water; insoluble
to ethanol
pH Between 7.0 and 7.5 (1% aqueous solution) –
Purity
Loss on drying Not more than 17.0% (105°C, 4 h) Not more than 17.0% and not less than
14% (105°C, 3 h)
Oxalates Not more than 100 mg/kg (expressed as oxalic
acid, after drying)
(a)
Arsenic Not more than 3 mg/kg –
Re-evaluation of tartaric acid-tartrates (E 334-337, 354)
www.efsa.europa.eu/efsajournal 15 EFSA Journal 2020;18(3):6030
Commission Regulation 231/2012 JECFA (2009)
Lead Not more than 2 mg/kg Not more than 2 mg/kg
Mercury Not more than 1 mg/kg –
pH – 7.0–7.5 (1 in 10 solution)
(a): The Panel noted that JECFA describes an analytical test for oxalates.
Table 4: Specifications for monopotassium tartrate (E 336 (i)) according to Commission Regulation
(EU) No 231/2012
Commission Regulation 231/2012
Assay Content not less than 98% on the anhydrous basis
Description White crystalline or granulated powder
Identification
Test for tartrate Passes test
Test for potassium Passes test
Melting point 230°C
pH 3.4 (1% aqueous solution)
Purity
Loss on drying Not more than 1.0% (105°C, 4 h)
Oxalates Not more than 100 mg/kg (expressed as oxalic acid, after drying)
Arsenic Not more than 3 mg/kg
Lead Not more than 2 mg/kg
Mercury Not more than 1 mg/kg
Table 5: Specifications for dipotassium tartrate (E 336 (ii)) according to Commission Regulation
(EU) No 231/2012
Commission Regulation 231/2012
Assay Content not less than 99% on the anhydrous basis
Description White crystalline or granulated powder
Identification
Test for tartrate Passes test
Test for potassium Passes test
pH Between 7.0 and 9.0 (1% aqueous solution)
Purity
Loss on drying Not more than 4.0% (105°C, 4 h)
Oxalates Not more than 100 mg/kg (expressed as oxalic acid, after drying)
Arsenic Not more than 3 mg/kg
Lead Not more than 2 mg/kg
Mercury Not more than 1 mg/kg
Table 6: Specifications for potassium sodium tartrate (E 337) according to Commission Regulation
(EU) No 231/2012 and JECFA (JECFA, 2006)
Commission Regulation 231/2012 JECFA (2006)
Assay Content not less than 99% on the anhydrous
basis
Not less than 99% after drying
Description Colourless crystals or white crystalline powder Colourless crystals, or as white, crystalline
powder
Identification
Test for tartrate Passes test Passes test
Test for
potassium
Passes test Passes test
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The Panel noted that provisions of Appendix 1 ‘Tartaric acid ((L(+))-) and derived products’ of
Commission Regulation (EC) No 934/2019 only apply to the L(+)tartaric acid used in FC 14.2.2. The
provisions of the above-mentioned Appendix 1 for tartaric acid do not have any application for the
food additive L(+)-tartaric acid (E 334) in accordance with Regulation (EC) No 1333/2008 in food
categories other than FC 14.2.2., which needs to comply with the specifications in Commission
Regulation (EU) No 231/2012.
The Panel noted that, according to the EU specifications for monosodium tartrate (E 335 (i)),
disodium tartrate (E 335 (ii)), monopotassium tartrate (E 336 (i)), dipotassium tartrate (E 336 (ii)),
potassium sodium tartrate (E 337) and calcium tartrate (E 354), impurities of the toxic elements
arsenic, lead and mercury are accepted up to concentrations of 3, 2 and 1 mg/kg, respectively.
Moreover, according to the European Commission specifications for L(+)-tartaric acid (E 334),
impurities of the toxic elements, lead and mercury are accepted up to concentrations of 2 and 1 mg/
kg, respectively. Contamination at those levels could have a significant impact on the exposure, which
are already close to the health-based guidance values or benchmark doses (lower confidence limits)
established by EFSA (EFSA CONTAM Panel, 2009, 2010, 2012a,b, 2014).
The Panel noted that there is a provision for specific rotation only for L(+)-tartaric acid (E 334) and
calcium tartrate (E 354). This provision is missing in the EU specifications for tartrates (E 335-337) and
it should be introduced in order to ensure the exclusive use of the authorised L(+) stereoisomer.
Commission Regulation 231/2012 JECFA (2006)
Test for sodium Passes test Passes test
Solubility 1 g is soluble in 1 mL of water, insoluble in
ethanol
One gram is soluble in 1 mL of water; insoluble
in ethanol
Melting range 70–80°C –
pH Between 6.5 and 8.5 (1% aqueous solution) 6.5–7.5 (1 in 10 solution)
Purity
Loss on drying Not more than 26.0% and not less than 21.0%
(105°C, 3 h)
Not more than 26.0% and not less than 21.0%
(105°C, 3 h)
Oxalates Not more than 100 mg/kg (expressed as oxalic
acid, after drying)
(a)
Arsenic Not more than 3 mg/kg –
Lead Not more than 2 mg/kg Not more than 2 mg/kg
Mercury Not more than 1 mg/kg –
(a): The Panel noted that JECFA describes an analytical test for oxalates.
Table 7: Specifications for calcium tartrate (E 354) according to Commission Regulation (EU)
No 231/2012
Commission Regulation 231/2012
Assay Content not less than 98.0%
Description Fine crystalline powder with a white or off-white colour
Identification
Solubility Slightly soluble in water. Solubility approximately 0.01 g/100 mL water (20°C). Sparingly
soluble in ethanol. Slightly soluble in diethyl ether. Soluble in acids
Specific rotation [a]D
20 + 7.0° to + 7.4° (0.1% in a 1N HCl solution)
pH Between 6.0 and 9.0 (5% slurry)
Purity
Sulphates Not more than 1 g/kg (as H2SO4)
Arsenic Not more than 3 mg/kg
Lead Not more than 2 mg/kg
Mercury Not more than 1 mg/kg
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3.1.3. Manufacturing process
L(+)-Tartaric acid
Information provided by industry
As a by-product of wine production
According to information provided by industry (NATEL, 2017 (Documentation provided to EFSA
No. 9)), L(+) tartaric acid is produced from tartar, lees of wine and/or grape pomace. Usually, tartaric
acid is present in these products as monopotassium tartrate (e.g. 80–90% in tartar) and, to a lesser
extent, calcium tartrate.
From the workflow provided by industry (NATEL, 2017 (Documentation provided to EFSA No. 9)),
tartar, lees and grape marc are neutralised by calcium hydroxide or calcium carbonate producing
calcium tartrate after concentration and centrifugation. Calcium tartrate is further treated with sulfuric
acid in a decomposing tank to produce tartaric acid that is purified by concentration and crystallisation.
Similar information is available from the literature and patents (Dabul et al., 1963; Kassaian, 2012).
From chemical/microbiological production
L(+)-Tartaric acid is manufactured from maleic anhydride that is converted to disodium cis-
epoxysuccinate solution (no detailed information on this step is provided by industry; catalysts contain
alkali metal salts of tungstic acid and molybdic acid, such as sodium tungstate dihydrate and sodium
molybdate dihydrate can be used for this reaction) (Documentation provided to EFSA No. 7).
Disodium cis-epoxysuccinate is converted to disodium L(+)-tartaric acid by bioconversion using cis-
epoxysuccinate hydrolase produced by an immobilised microorganism. Interested parties have
provided detailed information on the characterisation of two microorganisms declared to be used in
this step for the manufacturing of L(+)-tartaric acid. Disodium L(+)-tartaric acid is transformed to
calcium tartrate by treatment with a calcium salt. Calcium tartrate is converted to L(+)-tartaric acid by
a procedure as described above, with the addition of a further step where DL-tartaric acid is removed
by crystallisation from the crude L(+)-tartaric acid solution (Documentation provided to EFSA No. 7).
Information on maleic anhydride as a raw material
Maleic anhydride is the starting material converted enzymatically to L(+)-tartaric acid. Butane is
partially oxidised to maleic anhydride in the presence of vanadyl-phosphate as catalyst. In the
manufacturing process, azeotropic distillation is carried out at atmospheric pressure using xylene as
dehydrated agent (Documentation provided to EFSA No. 7).
The Panel considered that the presence of heavy metals (such as vanadium, molybdenum and
tungsten) in samples of L(+)-tartaric acid (Documentation provided to EFSA No. 8) can be due to the
use of catalysts in the conversion of butane to maleic anhydride and maleic anhydride to disodium cis-
epoxysuccinate solution. Therefore, maximum limits for heavy metals resulting from the use of any
catalyst that could be present in L(+)-tartaric acid due to its manufacturing process should be included
in the EU specifications for this food additive.
Rhodococcus sp strain USA-AN012 (Documentation provided to EFSA No. 6 and 7)
The L(+)-tartaric acid is obtained by biocatalysis using immobilised cells of the bacteria
Rhodococcus sp strain USA-AN012. Phylogenetic analysis of the 16S rRNA gene situates this strain as
probably belonging to R. aetherovorans (G€urtler et al., 2004; Frascari et al., 2006). R. aetherovorans is
a Gram-positive soil bacterium which has not been associated to human infections. The strain is not
genetically modified. No cytotoxicity was found in supernatants of the strain Rhodococcus sp strain
USA-AN012 when tested on CHO-K1 (Chinese Hamster Ovary) cells.16 The strain was tested for
susceptibility to antimicrobials according to the EFSA Guidance (EFSA FEEDAP Panel, 2018) and
resulted resistant to gentamycin compared with the reference values of minimum inhibitory
concentration (MIC) provided for ‘other gram-positives’.17 The nature of the resistance remains
unknown.
No viable microbial cells were found in three samples of L(+)-tartaric acid (1.3 g each, tested in
triplicate), by plating on non-selective solid medium and incubating at 37°C for 3 days. Likewise, no
DNA corresponding to a Polymerase Chain Reaction (PCR) based amplification of a region of the RbpA
16 Appendix C.
17 Appendix D.
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gene from Rhodococcus sp. USA-AN012 was found when cells of this strain were suspended in 700 g/L
of L(+)-L-tartaric acid and heated at 65°C for 8 h (conditions which mimic the crystallisation and
concentration steps of the L(+)-tartaric acid). This indicates that the manufacturing conditions of L(+)-
tartaric acid are sufficient to remove the production strain and to degrade its DNA, and therefore, the
Panel considered the product to be free from the Rhodococcus sp. USA-AN012 and its DNA.
Rhodococcus ruber strain CM001 (Documentation provided to EFSA No. 3)
No information on the general manufacturing process of L(+)-tartaric acid using this microorganism
was provided. The industry mentioned maleic anhydride as raw material; thus, the Panel assumed that
they use a similar procedure as described above using Rhodococcus sp strain USA-AN012.
The L(+) tartaric acid is obtained by biocatalysis using immobilised cells of the bacteria Rhodococcus
ruber strain CM001. The strain was identified as R. ruber by phylogenetic analysis of the 16S rRNA
gene. R. ruber is a gram-positive soil bacterium which has not been associated with human infections.
The strain is not genetically modified. R. ruber CM001 was tested for susceptibility to antimicrobials
according to the EFSA Guidance (EFSA FEEDAP Panel, 2018) and resulted sensitive to all antimicrobials
requested for ‘other gram-positives’.
The Panel considered that the manufacturing process of L(+)-tartaric acid from chemical/
microbiological production may result in impurities different from those that may be present in L(+)-
tartaric acid as a by-product of wine production. The Panel, therefore, considered that separate
specifications would be needed for L(+)-tartaric acid from chemical/microbiological production using
Rhodococcus ruber strain CM001 or Rhodococcus sp strain USA-AN012.
The Panel noted that in the peer-reviewed literature the manufacturing process of L(+)-tartaric acid
using other microorganisms for the bioconversion are described (Tsurumi and Fujioka, 1978; Kamatani
et al., 1987; Mikova et al., 1998; Rosenberg et al., 1999; Bucko et al., 2004; Willaert and De Vuyst,
2006; Cheng et al., 2014; Bao et al., 2015; E. Hoffmann et al., 2016; Hronska, 2017; Wang et al.,
2017). However, no interested parties have indicated their use and, therefore, they have not been
assessed by the Panel.
Monopotassium tartrate
From the workflow provided by industry (NATEL, 2017 (Documentation provided to EFSA No. 9)),
monopotassium tartrate is produced by neutralisation of crude tartaric acid with potassium carbonate
and it is purified by centrifugation and then dried.
According to Blair and DeFraties (2000), monopotassium tartrate can be produced:
• from argols (which are the crystalline crusts that form in the vats in the secondary
fermentation period) after a treatment with sodium carbonate;
• from a solution of L(+) tartaric acid with the addition of a liquor of potassium sodium tartrate
(also cited by Kassaian (2012));
• from of a water suspension of the argols after the saturation with sulfur dioxide.
The precipitated potassium tartrate is recovered by centrifugation, washed, dried and ground. The
substance so obtained is 99.9% pure (Blair and DeFraties (2000) and Kassaian (2012)).
Kherisi et al. (2015) described a process for manufacturing monopotassium tartrate from wine
tartar (lees) followed by purification.
Potassium sodium tartrate
From the workflow provided by industry (NATEL, 2017 (Documentation provided to EFSA No. 9)),
tartar, lees and grape marc are neutralised by sodium hydroxide or sodium carbonate. Sodium
potassium tartrate is purified by filtration, centrifugation and dried.
According to Kassaian (2012), potassium sodium tartrate is manufactured using monopotassium
tartrate with a low content (about 68%) of tartaric acid as starting material. Tartar, diluted in water, is
brought to pH 8 by adding sodium carbonate or sodium hydroxide. The precipitate so obtained is
decolourised with activated coal, washed, filtered, centrifuged, evaporated (at 100°C to specific gravity
of 1.41), and allowed to crystallise on slow cooling to produce potassium sodium tartrate.
Calcium tartrate
As mentioned above, calcium tartrate is the starting material for the production of tartaric acid
(NATEL, 2017 (Documentation provided to EFSA No. 9)).
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A short description of the production of calcium tartrate is given in the papers by Audinos and Paci
(1992) and Blair and DeFraties (2000). In the process, potassium bitartrate contained in the lees of
wine reacted with calcium hydroxide and calcium sulfate according to the following reaction,
2 KHC4H4O6 + Ca(OH)2 + CaSO4 ? 2 CaC4H4O6 + K2SO4 + 2H2O
Calcium tartrate is insoluble and precipitates.
No information on the manufacturing process of disodium tartrate and dipotassium tartrate was
available to the Panel.
3.1.4. Methods of analysis in food
According to the International Organisation of Vine and Wine (OIV), which is the recommended
basis for analytical methods in wines (Regulation 1308/2013), the reference method (OIV-MA-AS313-
05A) for the determination of L(+)-tartaric acid in wine consists of a precipitation step followed by
gravimetric measurement (OIV, online).
A range of chromatographic techniques for the analysis of L(+)-tartaric acid and its sodium,
potassium and calcium salts in food have been described in the published literature. These include:
High-Performance Liquid Chromatography (HPLC)
There are a number of publications with various chromatographic conditions, which are all based
on Reversed Phase HPLC separation: 1. Radin et al. (1994) with UV-detection at 210 nm in wine,
partially validated; 2. Scherer et al. (2012) used UV-detection at 210 nm in fruits and juices with a
limit of detection (LOD) of 0.72 mg/L; 3. Paredes et al. (2006) used three different detectors coupled
with the HPLC and demonstrated three different LODs 3.1 mg/L (ICP-AES for carbon), 1.2 mg/L
(Refractive Index) and 17 mg/L (UV-detection) in juices, wines and non-alcoholic drinks; 4. Rhaghav
et al. (2012), used a UV detection at 214 nm to measure tartaric acid in juices, where no information
on the validation of the method was available; 5. Mortera et al. (2017) analysed tartaric acid by using
a diode-array (DAD) detector and measured it at 210 nm together with an identification of the peak;
6. Park et al. (2017) used UV detection at 210 nm and analysed wine and beer with no further
information on the validation of the method; 7. Restuccia et al. (2017) used an Electronic Light
Scattering Detector to analyse, among others organic acids, tartaric acid in juices with a LOD of
3.18 mg/L.
Ion chromatography
Kupina et al. (1991) analysed grape juice and wines, where recovery rates were estimated but no
further information on the validation of the method is reported. Castro et al. (2002) compared the
results of the analysis of tartaric acid in sherry wine vinegar via Ion Exclusion Chromatography with
those obtained via Capillary Electrophoresis (CE) and concluded that both methods are applicable for
this purpose. Jin et al. (2010) presented a validated method of Ion Chromatography combined with
ElectroSpray Ionisation and MS detection reaching a Limit of Quantification (LOQ) of 0.05 mg/L in
wines and beverages.
Capillary electrophoresis (CE)
Kandl and Kupina (1999) used CE equipped with a DAD detector to analyse tartaric acid in wines
and fruit juices, where the partial validation of the method was demonstrated and the results were
compared with the ones obtained via Ion Chromatography. Karovicova et al. (1990) used CE to
analyse tartaric acid in red wines but no information on the validation of the method was available.
Treilhou et al. (2001) presented a CE analytical method with indirect UV detection for wine and
beverages, with a LOQ of 0.28 mg/L. Kodoma et al. (2001) demonstrated the analytical separation and
measurement of D(-) and L(+) tartaric acid via CE equipped with UV detector in various food items
(e.g. sake, candies, grape juice and red wine). Vickers et al. (2007) developed a method to separate
and detect the two chiral isomers of tartrates in spiked samples matrices (e.g. cocoa, jam, lemonade,
sugar syrup) with a LOD of 10 mg/L, based on the calibration curve.
Capillary zone electrophoresis (CZE) coupled to ESI/QTOF-MS has been reported as a method for
quantitative determination of tartaric acid, together with other five organic acid, in red wine (Ivanova-
Petropulos et al., 2018). The validation parameters, including linearity of concentration curve, LOQ
(0.038 mM, equivalent to 5.7 mg/L), recovery, repeatability and reproducibility, were determined for
each acid.
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Other methodologies
Chine et al. (1994) demonstrated that isotachophoresis can be applied for the analysis of tartaric
acid in juices and soft drinks. The method has been only partially validated. Fourier Transform IR
(FTIR) analysis has been used by Le Thahn et al. (2000) to estimate the tartaric acid content in soft
drinks after a solid phase extraction step, without any information on the validation of the method.
Ayora-Ca~nada et al. (2000) also used flow injection analysis (FIA)-FTIR with a pH modulation for the
analysis of tartaric acid in soft drinks.
3.1.5. Stability of the substance, and reaction and fate in food
The stability of the food additive L(+) tartaric acid (E 334) over a period of 3 years as a packaged
food additive regarding its compliance with the purity criteria (appearance and physical/chemical
parameters) under the recommended storage temperature has been reported without change in the
assay (%) or specific rotation (CMBEC, 2017 (Documentation provided to EFSA No. 2)).
Tartaric acid and its salts (potassium bitartrate and calcium tartrate) are naturally present in wine.
The Panel noted that in wine, during alcoholic fermentation and during storage, potassium bitartrate
and/or calcium tartrate precipitate or crystallise. The stability (solubility) of the tartrates depends on
the alcohol content, pH and temperature as well as interactive effects of the solution matrix with the
cations (K and Ca) and the bitartrate/tartrate anions (Zoecklein et al., 1990; Gerbaud et al., 2010).
According to Marchal and Jeandet (2009), free tartaric acid can be complexed with proteins and
polyphenols in certain wines, thus inhibiting potassium bitartrate crystal formation.
The Panel noted that tartaric acid has been reported to decompose at temperatures above 180°C
(Chattaway and Ray, 1921); however, no data were identified on the fate of tartaric acid during food
processing such as baking.
In view of the de-acidification of wines, Gao and Fleet (1995) examined the ability of high-density
cell suspensions of several yeast species to degrade L(+)-tartaric acids and L(+)-malic in view of the de-
acidification of wines. Data show that weak or no degradation of tartaric acid occurred.
3.2. Authorised uses and use levels
Maximum levels of tartaric acid and tartrates (E 334-337; E 354) have been defined in Annex II to
Regulation (EC) No 1333/200818 on food additives, as amended. In this document, these levels are
named maximum permitted levels (MPLs).
Currently, tartaric acid and tartrates (E 334-337 and E 354) are authorised in the EU at quantum
satis (QS) in almost all food categories (FCs) listed in Table 8. In FCs 13.1.3 and 13.1.5.2, tartaric acid
and tartrates (E 334-337 and E 354) are permitted at an MPL of 5,000 mg/kg. Tartaric acid and
tartrates (E 334-337 and E 354) are included in the Group I of food additives. Table 8 summarises the
food categories that are permitted to contain tartaric acid and tartrates (E 334-337 and E 354) and
the corresponding MPLs as set by Annex II to Regulation (EC) No 1333/2008.
Table 8: MPLs of tartaric acid and tartrates (E 334-337 and E 354) in foods according to the Annex II












01.3 Unflavoured fermented milk products,
heat treated after fermentation
Group I quantum satis
01.4 Flavoured fermented milk products
including heat-treated products
Group I quantum satis
01.6.3 Other creams Group I quantum satis
01.7.1 Unripened cheese excluding products
falling in category 16
Group I Except mozzarella quantum satis
01.7.5 Processed cheese Group I quantum satis
18 Regulation (EC) No 1333/2008 of the European Parliament and of the Council of 16 December 2008 on food additives. OJ L
354, 31.12.2008, p. 16.
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01.7.6 Cheese products (excluding products
falling in category 16)
Group I quantum satis
01.8 Dairy analogues, including beverage
whiteners
Group I quantum satis
02.2.2 Other fat and oil emulsions including
spreads as defined by Council
Regulation (EC) No 1234/2007 and
liquid emulsions
Group I quantum satis
02.3 Vegetable oil pan spray Group I quantum satis
03 Edible ices Group I quantum satis
04.2.1 Dried fruit and vegetables Group I quantum satis
04.2.2 Fruit and vegetables in vinegar, oil or
brine
Group I quantum satis
04.2.3 Canned or bottled fruit and
vegetables
E 334 / E 335
/ E 336 /
E 337
quantum satis
04.2.4.1 Fruit and vegetable preparations
excluding compote
Group I quantum satis
04.2.5.1 Extra jam and extra jelly as defined
by Directive 2001/113/EC
E 334 / E 335 quantum satis
04.2.5.2 Jam, jellies and marmalades and
sweetened chestnut puree as defined
by Directive 2001/113/EC
E 334 / E 335 quantum satis
04.2.5.3 Other similar fruit or vegetable
spreads
E 334 / E 335 quantum satis
04.2.5.4 Nut butters and nut spreads Group I quantum satis
04.2.6 Processed potato products Group I quantum satis
05.1 Cocoa and Chocolate products as
covered by Directive 2000/36/EC
Group I Only energy-reduced or
with no added sugar
quantum satis
05.1 Cocoa and Chocolate products as
covered by Directive 2000/36/EC
E 334 5,000
05.2 Other confectionery including breath
freshening microsweets
Group I quantum satis
05.3 Chewing gum Group I quantum satis
05.4 Decorations, coatings and fillings,
except fruit-based fillings covered by
category 4.2.4
Group I quantum satis
06.2.2 Starches Group I quantum satis
06.3 Breakfast cereals Group I quantum satis
06.4.1 Fresh pasta E 334 quantum satis







06.4.3 Fresh pre-cooked pasta E 334 quantum satis




06.4.4 Potato Gnocchi E 334 Only fresh refrigerated
potato gnocchi
quantum satis
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06.4.5 Fillings of stuffed pasta (ravioli and
similar)
Group I quantum satis
06.5 Noodles Group I quantum satis
06.6 Batters Group I quantum satis
06.7 Pre-cooked or processed cereals Group I quantum satis
07.1 Bread and rolls Group I Except products in
7.1.1 and 7.1.2
quantum satis
07.2 Fine bakery wares Group I quantum satis
08.3.1 Non-heat-treated meat products Group I quantum satis
08.3.2 Heat-treated meat products Group I Except foie gras, foie





08.3.3 Casings and coatings and decorations
for meat
Group I quantum satis
09.2 Processed fish and fishery products
including molluscs and crustaceans
Group I quantum satis
09.3 Fish roe Group I Only processed fish roe quantum satis
10.2 Processed eggs and egg products Group I quantum satis
11.2 Other sugars and syrups Group I quantum satis
11.4.2 Table-Top sweeteners in powder form E 336 quantum satis
11.4.3 Table-top sweeteners in tablets E 334/E 335/
E 336
quantum satis
12.1.2 Salt substitutes Group I quantum satis
12.2.2 Seasonings and condiments Group I quantum satis
12.3 Vinegars and diluted acetic acid
(diluted with water to 4–30% by
volume)
Group I quantum satis
12.4 Mustard Group I quantum satis
12.5 Soups and broths Group I quantum satis
12.6 Sauces Group I quantum satis
12.7 Salads and savoury-based sandwich
spreads
Group I quantum satis
12.8 Yeast and yeast products Group I quantum satis
12.9 Protein products, excluding products
covered in category 1.8
Group I quantum satis
13.1.3 Processed cereal-based foods and
baby foods for infants and young




only biscuits and rusks
and baby foods
5,000(a)
13.1.3 Processed cereal-based foods and
baby foods for infants and young
children as defined by Directive
2006/125/EC2006/125/EC
E 354 only biscuits and rusks 5,000(a)
13.1.5.2 Dietary foods for babies and young
children for special medical purposes
as defined in Directive 1999/21/EC
E 334/E 335/
E 336
Only biscuits and rusks
and baby foods
5,000(a)
13.1.5.2 Dietary foods for babies and young
children for special medical purposes
as defined in Directive 1999/21/EC
E 354 Only biscuits and rusks 5,000(a)
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13.2 Dietary foods for special medical
purposes defined in Directive
1999/21/EC (excluding products from
food category 13.1.5)
Group I quantum satis
13.3 Dietary foods for weight control diets
intended to replace total daily food
intake or an individual meal (the
whole or part of the total daily diet)
Group I quantum satis
13.4 Foods suitable for people intolerant to
gluten as defined by Regulation (EC)
No 41/2009
Group I Including dry pasta quantum satis
14.1.2 Fruit juices as defined by Directive
2001/112/EC and vegetable juices
Group I Only vegetable juices quantum satis
14.1.2 Fruit juices as defined by Directive
2001/112/EC and vegetable juices
E 336 Only grape juice quantum satis
14.1.3 Fruit nectars as defined by Directive
2001/112/EC and vegetable nectars
and similar products
Group I Only vegetable nectars quantum satis
14.1.4 Flavoured drinks Group I quantum satis




14.2.3 Cider and perry Group I quantum satis
14.2.4 Fruit wine and made wine Group I quantum satis
14.2.5 Mead Group I quantum satis
14.2.6 Spirit drinks as defined in Regulation
(EC) No 110/2008
Group I Except whisky or
whiskey
quantum satis
14.2.7.1 Aromatised wines Group I quantum satis
14.2.7.2 Aromatised wine-based drinks Group I quantum satis
14.2.7.3 Aromatised wine-product cocktails Group I quantum satis
14.2.8 Other alcoholic drinks including
mixtures of alcoholic drinks with non-
alcoholic drinks and spirits with less
than 15% of alcohol
Group I quantum satis
15.1 Potato-, cereal-, flour- or starch-based
snacks
Group I quantum satis
15.2 Processed nuts Group I quantum satis
16 Desserts excluding products covered
in categories 1, 3 and 4
Group I quantum satis
17.1 Food supplements supplied in a solid
form, excluding food supplements for
infants and young children
Group I quantum satis
17.2 Food supplements supplied in a liquid
form, excluding food supplements for
infants and young children
Group I quantum satis
18 Processed foods not covered by
categories 1 to 17, excluding foods
for infants and young children
Group I quantum satis
MPL: maximum permitted level.
(a): As a residue (Regulation (EC) No 1333/2008), with the intention to have not more than 5,000 mg/kg as a residue for all
tartrates.
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The Panel considered that ‘residue’ as mentioned in footnote (Table 8) corresponds to the total
amount of tartrate in the food resulting from the added tartaric acid and tartrates (E 334-337 and
E 354) as food additives and the presence of tartaric acid from natural origin.
The Panel noted that the restriction applicable to FC 13.1.5.2 ‘Only L(+)-form; only biscuits and
rusks and baby foods’ excludes the use of E 334, E 335, E 336 and E 354 as food additives in food for
infants under the age of 16 weeks.
In addition to the authorised uses in accordance with Annex II, Part E of Regulation (EC) No 1333/2008
(Table 8), (L)-tartaric acid (E 334) is authorised to be used as a food additive (acidity regulator) in wine
according to Regulation (EC) No 934/2019. Limits for acidification or de-acidification using any of the
oenological compounds listed as acidity regulators in Regulation (EC) No 934/2019 are established in
Regulation (EU) No 1308/2013.19
Tartaric acid and tartrates (E 334-337 and E 354) are also authorised according to Annex III of
Regulation (EC) No 1333/2008.
According to Annex III, Part 2 of Regulation (EC) No 1333/2008, tartaric acid and tartrates (E 334-
337 and E 354) are authorised as food additives in food additives having a function other than a
carrier with a maximum level in the products (beverages or not) at QS.
According to Annex III, Part 3 of Regulation (EC) No 1333/2008, tartaric acid and tartrates (E 334-
337 and E 354) are authorised as food additives in food enzymes with a maximum level in the
products (beverages or not) at QS.
According to Annex III, Part 4 of Regulation (EC) No 1333/2008, tartaric acid and tartrates (E 334-
337 and E 354) are authorised as food additives including carriers in all food flavourings with a
maximum level in the products (beverages or not) at QS.
In addition, according to Annex III, Part 5, Section A of Regulation (EC) No 1333/2008, tartaric acid
and tartrates (E 334-337 and E 354) are authorised in all nutrients with a maximum level in the
nutrient at QS.
3.3. Exposure data
3.3.1. Reported use levels or data on analytical levels of tartaric acid-tartrates
(E 334-337, 354)
Most food additives in the EU are authorised at a specific MPL. However, a food additive may be
used at a lower level than the MPL. Therefore, information on actual use levels is required for
performing a more realistic exposure assessment, especially for those food additives for which no MPL
is set and which are authorised according to QS.
In the framework of Regulation (EC) No 1333/2008 on food additives and of Commission
Regulation (EU) No 257/2010 regarding the re-evaluation of approved food additives, EFSA issued two
public calls20,21 for occurrence data (use level and/or concentration data) on tartaric acid and tartrates
(E 334-337 and E 354). In response to these calls, both types of data on tartaric acid and tartrates
(E 334-337 and E 354) were submitted to EFSA by industry and Member States, respectively.
Summarised data on reported use levels in foods provided by industry
Industry provided EFSA with data on use levels (n = 83) of tartaric acid and tartrates (E 334-337
and E 354) in foods for 17 out of the 81 food categories in which these food additives are authorised
according to Regulation (EC) No 1333/2008. Furthermore, use levels of tartaric acid (E 334) and
monopotassium tartrate (E 336) for sparkling wines and vermouth were provided by CEEV (Comite
Europeen des Entreprises Vins), as according to Commission Regulation (EC) No 934/2019.
Updated information on the actual use levels of tartaric acid and tartrates (E 334-337 and E 354) in
foods was made available to EFSA by the Association of the European Self-Medication Industry
(AESGP), European Dairy Association (EDA), European Snacks Association/SNACMA (ESA), Food Drink
Europe (FDE), Food Supplements Europe (FSE), HiPP-Werk Georg Hipp OHG (HIPP), IMACE,
International Chewing Gum Association (ICGA), ROSHEN and Specialised Nutrition Europe (SNE).
19 Regulation (EU) No 1308/2013 of the European Parliament and of the Council of 17 December 2013 establishing a common
organisation of the markets in agricultural products and repealing Council Regulations (EEC) No 922/72, (EEC) No 234/79,
(EC) No 1037/2001 and (EC) No 1234/2007. OJ L 347, 20.12.2013, p. 671–854.
20 http://www.efsa.europa.eu/sites/default/files/consultation/ans15062010%2C0.pdf
21 http://www.efsa.europa.eu/sites/default/files/consultation/160524.pdf
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Industry reported 67 levels for E 334, 1 for E 335, 13 for E 336 and 2 for E 337. No use levels
were reported for E 354. The Panel noted that 14 use levels referred to niche products. These levels
are only considered if no other use levels are available for the food categories to which the niche
products belong. In the current assessment, the 14 use levels were not included in the refined
assessment. Use levels in niche products were considered in the maximum level exposure scenario, if
those levels were higher than the other use levels reported within the food category.
Appendix A provides an overview of the use levels of tartaric acid and tartrates (E 334-337 and
E 354) in foods as reported by industry.
Summarised data on analytical results in food submitted by Member States
In total, 1212 analytical results were reported to EFSA by one Spanish laboratory. This laboratory
provided analytical data of samples obtained from four countries: Germany (n = 310), Hungary
(n = 302), Spain (n = 304) and UK (n = 296). These data were mainly for snack food (FC 15.1) and
flavoured drinks (FC 14.1.4). The other data were on other confectionery including breath freshening
micro-sweets (FC 05.2), fruit juices (FC 14.1.2) and fruit nectars (FC 14.1.3). Foods were all sampled
in 2013. All samples were analysed for sodium tartrate through a capillary (zone) electrophoresis (CE
or CZE) method, performed in an accredited laboratory.
Overall, 92% of the analytical results on tartaric acid and tartrates (E 334-337 and E 354) were not
quantified (< LOQ, left-censored). All analytical results were left-censored for the FCs 14.1.3 Fruit
nectars as defined by Directive 2001/112/EC and vegetable juices and 14.1.4 Favoured drinks. The
LOQs ranged from 50 to 2,875 mg/L (kg).
The Panel considered the analytical data unsuitable for the estimation of the exposure to tartrates
that occur naturally in the diet, due to the high percentage of left-censored data, the high limit of
quantification (up to 2,875 mg/kg for some samples) and because these data do not allow the
estimation of the exposure from natural sources only.
Appendix B shows the analytical results of tartaric acid and tartrates (E 334-337 and E 354) in
foods as reported by Member States.
3.3.2. Summarised data extracted from the Mintel’s Global New Products
Database
The Mintel’s GNPD is an online database which monitors new introductions of packaged goods in
the market worldwide. It contains information of over 3 million food and beverage products of which
more than 1,100,000 are or have been available on the European food market. Mintel started covering
EU’s food markets in 1996, currently having 25 out of its 28 Member Countries and Norway presented
in the GNPD.22
For the purpose of this Scientific Opinion, Mintel’s GNPD23 was used for checking the labelling of food
and beverages products and food supplements for tartaric acid and tartrates (E 334-337 and E 354)
within the EU’s food market as the database contains the compulsory ingredient information on the label.
According to Mintel’s GNPD, tartaric acid and tartrates (E 334-337 and E 354) were labelled on
around 4,700 products between January 2014 and November 2019.
Appendix C.1 lists the percentage of the products labelled with tartaric acid and tartrates (E 334-
337 and E 354) out of the total number of products per food subcategory according to Mintel’s GNPD
food classification. The percentages ranged from less than 0.1% in many food subcategories to 19.3%
in food subcategory ‘Baby Biscuits & Rusks’ and ‘Standard & Power Mints’. The average percentage of
foods labelled with tartaric acid and tartrates (E 334-337 and E 354) was 1.0%.
The Panel noted that according to Mintel’s GNPD, tartaric acid (E 334) was used most frequently
(almost 60%) in food products labelled with tartaric acid and tartrates (E 334-337 and E 354). The
Panel also noted that only one food product (from the subcategory ‘Baking ingredients and mixes’)
was reported to be labelled with calcium tartrate (E 354).
Some food products for which no use levels were provided to EFSA were labelled with tartaric acid
and tartrates (E 334-337 and E 354), such as desserts (frozen, chilled and shelf-stable), sweeteners
and chocolate products. In total, 76 products were labelled with two different additives belonging to
tartaric acid and tartrates (E 334-337 and E 354) out of the 4730 products labelled with at least one
additive (Appendix C.2).
22 Missing Bulgaria, Cyprus, Estonia, Latvia, Lithuania, Luxembourg, Malta and Slovenia.
23 http://www.gnpd.com/sinatra/home/ accessed on 28/11/2019.
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3.3.3. Food consumption data used for exposure assessment
EFSA Comprehensive European Food Consumption Database
Since 2010, the EFSA Comprehensive European Food Consumption Database (Comprehensive
Database) has been populated with national data on food consumption at a detailed level. Competent
authorities in the European countries provide EFSA with data on the level of food consumption by the
individual consumer from the most recent national dietary survey in their country (cf. Guidance of
EFSA on the ‘Use of the EFSA Comprehensive European Food Consumption Database in Exposure
Assessment’ (EFSA, 2011a). Consumption surveys added in the Comprehensive database in 2015 were
also considered in this assessment.13
The food consumption data gathered by EFSA were collected by different methodologies and thus
direct country-to-country comparisons may not be appropriate. Depending on the food category and
the level of detail used for exposure calculations, uncertainties could be introduced owing to possible
subjects’ underreporting and/or misreporting of the consumption amounts. Nevertheless, the EFSA
Comprehensive Database includes the currently best available food consumption data across Europe.
Food consumption data from infants, toddlers, children, adolescents, adults and the elderly were
used in the exposure assessment. For the present assessment, food consumption data were available
from 33 different dietary surveys carried out in 19 European countries (Table 9).
Consumption records were codified according to the FoodEx classification system (EFSA, 2011b).
Nomenclature from the FoodEx classification system has been linked to the food categorisation system
(FCS) as presented in Annex II of Regulation (EC) No 1333/2008, part D, to perform the exposure
assessment. In practice, the FoodEx food codes were matched to the FCS food categories.
Food categories considered for the exposure assessment of tartaric acid and tartrates
(E 334-337 and E 354)
The 17 food categories, for which MPL or use levels of tartaric acid and tartrates (E 334-337 and
E 354) were available, were selected from the nomenclature of the EFSA Comprehensive Database
(FoodEx classification system), at the most detailed level possible (up to FoodEx Level 4) (EFSA,
2011b).
For the following food categories, the restrictions/exceptions which apply to the use of tartaric acid
and tartrates (E 334-337 and E 354) could not be considered, and therefore, the whole food category
Table 9: Population groups considered for the exposure estimates of tartaric acid and tartrates
(E 334-337 and E 354)
Population Age range
Countries with food consumption surveys
covering more than 1 day
Infants From more than 12 weeks up to and
including 11 months of age
Bulgaria, Denmark, Finland, Germany, Italy, UK
Toddlers(a) From 12 months up to and including
35 months of age
Belgium, Bulgaria, Denmark, Finland, Germany,
Italy, Netherlands, Spain, UK
Children(b) From 36 months up to and including
9 years of age
Austria, Belgium, Bulgaria, Czech Republic,
Denmark, Finland, France, Germany, Greece, Italy,
Latvia, Netherlands, Spain, Sweden, UK
Adolescents From 10 years up to and including 17 years
of age
Austria, Belgium, Cyprus, Czech Republic,
Denmark, Finland, France, Germany, Italy, Latvia,
Netherlands, Spain, Sweden, UK
Adults From 18 years up to and including 64 years
of age
Austria, Belgium, Czech Republic, Denmark,
Finland, France, Germany, Hungary, Ireland, Italy,
Latvia, Netherlands, Romania, Spain, Sweden, UK
The elderly(b) From 65 years of age and older Austria, Belgium, Denmark, Finland, France,
Germany, Hungary, Ireland, Italy, Romania,
Netherlands, Sweden, UK
(a): The term ‘toddlers’ in the EFSA Comprehensive Database (EFSA, 2011a) corresponds to ‘young children’ in Regulations (EC)
No 1333/2008 and (EU) No 609/2013.
(b): The terms ‘children’ and ‘the elderly’ correspond, respectively, to ‘other children’ and the merge of ‘elderly’ and ‘very elderly’
in the EFSA Comprehensive Database (EFSA, 2011a).
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was considered in the exposure assessment. This applied to two food categories and may have
resulted in an overestimation of the exposure:
• 07.1 Bread and rolls; except products in 7.1.1 and 7.1.2;
• 13.1.3 Processed cereal-based foods and baby foods for infants and young children as defined
by Directive 2006/125/E and 13.1.5.2 Dietary foods for babies and young children for special
medical purposes as defined in Directive 1999/21/EC, only L(+)-form; only biscuits and rusks
and baby foods.
Since a specific limit for (L)-tartaric acid is not defined in Regulation (EU) No 1308/2013, the use of
(L)-tartaric acid (E 334) as a food additive in wine (FC 14.2.2) was not considered in the maximum
level exposure assessment scenario (see Section 3.4.1).
For the FCs 17.1/17.2 Food supplements supplied in a solid or liquid form, excluding food
supplements for infants and young children, the form cannot be differentiated in the EFSA
Comprehensive Database, and therefore, the levels provided for the FCs 17.1 and 17.324 were used for
the whole FC 17.
Overall, 17 food categories were included in the present exposure assessment to tartaric acid and
tartrates (E 334-337 and E 354) (Appendix D).
3.4. Exposure estimates
3.4.1. Exposure to tartaric acid and tartrates (E 334-337 and E 354) from their
use as food additives
The Panel estimated the chronic dietary exposure to tartaric acid and tartrates (E 334-337 and E 354)
for the following population groups: infants, toddlers, children, adolescents, adults and the elderly. Based
on information from the Mintel’s GNPD, the Panel considered that tartaric acid and tartrates (E 334-337
and E 354) are not likely to be used in combination in the same food product and, therefore, the
exposure assessment of tartaric acid and tartrates (E 334-337 and E 354) was performed considering
the highest reported use level for either E 334, E 335, E 336, E 337 or E 354 per food category.
Dietary exposure to tartaric acid and tartrates (E 334-337 and E 354) was calculated by multiplying
the concentrations of tartaric acid and tartrates (E 334-337 and E 354) per food category (Appendix D)
with their respective consumption amount per kilogram body weight for each individual in the
Comprehensive Database. The exposure per food category was subsequently added to derive an
individual total exposure per day. These exposure estimates were averaged over the number of survey
days, resulting in an individual average exposure per day for the survey period. Dietary surveys with only
1 day per subject were excluded as they are considered as not adequate to assess repeated exposure.
This was carried out for all individuals per survey and per population group, resulting in
distributions of individual exposure per survey and population group (Table 9). On the basis of these
distributions, the mean and 95th percentile of exposure were calculated per survey and per population
group. The 95th percentile of exposure was only calculated for those population groups with a
sufficiently large sample size (EFSA, 2011a). Therefore, in the present assessment, the 95th percentile
of exposure for infants from Italy and for toddlers from Belgium, Italy and Spain was not estimated.
The exposure assessment to tartaric acid and tartrates (E 334-337 and E 354) was carried out by
the FAF Panel based on two different sets of concentration data: (1) MPLs combined with maximum
reported use levels (defined as the maximum level exposure assessment scenario); and (2) typical/
maximum reported use levels (defined as the refined exposure assessment scenario). These two
scenarios are discussed in detail below.
These scenarios do not consider the exposure to tartaric acid and tartrates (E 334-337 and E 354)
from the consumption of food supplements. This exposure source was covered in an additional
scenario detailed below (food supplements consumers only scenario).
A possible additional exposure to tartaric acid and tartrates (E 334-337 and E 354) as food additives
from their use in food additives, food enzymes, food flavourings and in nutrients in accordance with
Annex III to Regulation (EC) No 1333/2008 (Parts 2, 3, 4 and 5A, respectively) was not considered in
any of the exposure assessment scenarios, as no data were available reflecting this use.
24 Call for data on tartaric acid and tartrates (E 334-337 and E 354) was launched during batch 5, with deadline January 2017.
At the time, food additives legislation foresaw 3 food categories of food supplements (17.1, 17.2 and 17.3) depending on their
forms. In October 2018, Regulation (EC) No 1333/2008 was modified and food supplements are now subdivided into 2 food
categories of 17.1 and 17.2 (as mentioned in Table 8).
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Most of the reported use levels referred to tartaric acid (E 334) (n = 67 out of the 83 use levels).
The other levels were for sodium tartrate (E 335), potassium tartrate (E 336) and sodium potassium
tartrate (E 337). No reported use levels were submitted for calcium tartrate (E 354), which
corresponds with the information from Mintel GNPD. The use levels reported for its salts were
converted to tartaric acid. Therefore, the estimated exposure to tartaric acid and tartrates (E 334-337
and E 354) was expressed as mg tartaric acid/kg bw per day.
Maximum level exposure assessment scenario
The regulatory maximum level exposure assessment scenario is based on the MPLs as set in Annex
II to Regulation (EC) No 1333/2008. As tartaric acid and tartrates (E 334-337 and E 354) are
authorised according to QS in almost all food categories (Table 8), the ‘maximum level exposure
assessment’ scenario was based on the maximum reported use levels provided by industry and the
MPL for FCs 05.1 and 13.1.3, according to the EFSA Conceptual framework (EFSA ANS Panel, 2014).
The Panel considers the exposure estimates derived following this scenario as the most
conservative since it is assumed that the population will be exposed to the food additive present in
food at the maximum reported use levels over a longer period of time.
Refined exposure assessment scenario
The refined exposure assessment scenario for tartaric acid and tartrates (E 334-337 and E 354)
was based on use levels reported by the food industry, as the analytical data provided by the Member
States were considered unsuitable for this scenario (Section 3.3.1). Appendix D summarises the levels
used in this scenario. This exposure scenario can consider only food categories for which these data
were available to the Panel.
Based on the available data set, the Panel calculated two refined exposure estimates based on two
model populations:
• The brand-loyal consumer scenario: It was assumed that a consumer is exposed long term to
tartaric acid and tartrates (E 334-337 and E 354) present at the maximum reported use level
for one food category. This exposure estimate is calculated as follows:
– Combining food consumption with the maximum of the reported use levels for the main
contributing food category at the individual level.
– Using the mean of the typical reported use levels for the remaining food categories.
• The non-brand-loyal consumer scenario: It was assumed that a consumer is exposed long
term to tartaric acid and tartrates (E 334-337 and E 354) present at the mean reported use
levels in food. This exposure estimate is calculated using the mean of the typical reported use
levels for all food categories.
‘Food supplement consumers only’ scenario
Tartaric acid and tartrates (E 334-337 and E 354) are authorised in FCs 17.1 and 17.2 Food
supplements as defined in Directive 2002/46/EC excluding food supplements for infants and young
children. As exposure via food supplements may deviate largely from that via food, and the number of
food supplement consumers may be low depending on populations and surveys, an additional scenario
was calculated to reflect additional exposure to tartaric acid and tartrates (E 334-337 and E 354) from
food supplements. This additional exposure was estimated assuming that consumers of food
supplements were exposed to tartaric acid and tartrates (E 334-337 and E 354) present at the
maximum reported use level in food supplements on a daily basis. For the remaining food categories
(14/81 categories), the mean of the typical reported use levels was used.
As FCs 17.1 and 17.2 do not consider food supplements for infants and toddlers as defined in the
legislation, exposure to tartaric acid and tartrates (E 334-337 and E 354) from food supplements was
not estimated for these two population groups.
This scenario included 19 food categories (Appendix D).
Dietary exposure to tartaric acid and tartrates (E 334-337 and E 354)
Table 10 summarises the estimated exposure to tartaric acid and tartrates (E 334-337 and E 354)
from their use as food additives in six population groups (Table 9) according to the different exposure
scenarios. Detailed results per population group and survey are presented in Appendix E.
Re-evaluation of tartaric acid-tartrates (E 334-337, 354)
www.efsa.europa.eu/efsajournal 29 EFSA Journal 2020;18(3):6030
In the maximum level exposure assessment scenario, mean exposure to tartaric acid and tartrates
(E 334-337 and E 354) from their use as food additives ranged from 1 mg/kg bw per day to 214 mg/
kg bw per day, both in infants. The 95th percentile of exposure to tartaric acid and tartrates (E 334-
337 and E 354) ranged from 7 to 436 mg/kg bw per day, again in infants.
In the brand-loyal refined estimated exposure scenario, mean exposure to tartaric acid and tartrates
(E 334-337 and E 354) from their use as food additives ranged from less than 1 to 101 mg/kg bw per
day in infants. The high exposure to tartaric acid and tartrates (E 334-337 and E 354) ranged from
2 mg/kg bw per day in infants to 273 mg/kg bw per day in toddlers. In the non-brand-loyal scenario,
mean exposure to tartaric acid and tartrates (E 334-337 and E 354) from their use as food additives
ranged from below 1 to 91 mg/kg bw per day in infants. The 95th percentile of exposure to tartaric acid
and tartrates (E 334-337 and E 354) ranged from 2 to 174 mg/kg bw per day in infants.
In the food supplements consumers only scenario, mean exposure to tartaric acid and tartrates
(E 334-337 and E 354) from their use as food additives ranged from 8 mg/kg bw per day in
adolescents to 99 mg/kg bw per day in children. The 95th percentile of exposure to tartaric acid and
tartrates (E 334-337 and E 354) ranged from 19 mg/kg bw per day in adolescents to 93 mg/kg bw
per day in children. Detailed results per population group and survey for the food supplements
consumers only scenario are presented in Appendix G.
Tartaric acid and tartrates (E 334-337 and E 354) are used as ‘acidity regulator’ and are therefore
not expected to change the organoleptic properties of the final food at the concentration used as a
food additive. For this reason, the Panel considered the non-brand-loyal scenario covering the general
population as the most appropriate scenario for risk characterisation.
Main food categories contributing to exposure to tartaric acid and tartrates (E 334-337
and E 354)
FC 07.1 Bread and rolls was the major contributor to the mean exposure in all scenarios and
population groups. Other food categories that contributed significantly to the exposure in some
population groups were:
• In infants and toddlers:
o FC 13.1.3 Processed cereal-based foods and baby foods for infants and young children as
defined by Directive 2006/125/EC.
o FC 01.2 Unflavoured fermented milk products, including natural unflavoured buttermilk
(excluding sterilised buttermilk) non heat-treated after fermentation.
• In children and adolescents:
o FC 05.2 Other confectionery including breath freshening microsweets.
Table 10: Summary of dietary exposure to tartaric acid and tartrates (E 334-337 and E 354) from
their use as food additives in the maximum level exposure assessment scenario and in
the refined exposure scenarios, in six population groups (minimum–maximum across the
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• In all population groups, except infants.
o FC 07.2 Fine bakery wares.
• In all population groups, except infants and the elderly:
o FC 15.1. Potato-, cereal-, flour- or starch-based snacks in all population groups, except
infants and the elderly.
o FC 14.1.4 Flavoured drinks.
For the actual contributions per exposure scenario and population group, see Appendix F.
Uncertainty analysis
Potential sources of uncertainty in the exposure assessment of tartaric acid and tartrates (E 334-
337 and E 354) have been discussed above. In accordance with the guidance provided in the EFSA
opinion related to uncertainties in dietary exposure assessment (EFSA, 2007), the following sources of
uncertainties have been considered and summarised in Table 11.
Tartaric acid and tartrates (E 334-337 and E 354) are authorised as a Group I food additive in 66
food categories and have a specific authorised use in 15 food categories (Table 8). Since the majority
of food categories correspond to the general Group I food additives authorisation, the food additives
may not be used in all of these food categories. This may explain why reported use levels of tartaric
acid and tartrates (E 334-337 and E 354) were only available for 17 food categories. For the 15 food
categories with a specific use of these food additives, use levels were only reported for one food
category (FC 13.1.3). Furthermore, the Panel noted that the information from Mintel’s GNPD
(Appendix C.1) supported the observation that the food additives may not be used in all food
categories in which they are authorised.
The Panel also noted that of the 105 food subcategories, categorised according to Mintel’s GNPD
nomenclature and in which at least one food was labelled with tartaric acid and tartrates (E 334-337
and E 354), 42 were included in the exposure assessment. These 42 food subcategories represented
approximately 82% of the food products labelled with tartaric acid and tartrates (E 334-337 and
E 354) in Mintel’s GNPD. In the remaining 63 food subcategories, the main food category not included
in the exposure assessment was desserts (see Appendix C.1).
Table 11: Qualitative evaluation of influence of uncertainties on the dietary exposure estimate
Sources of uncertainties Direction(a)
Consumption data: different methodologies/representativeness/underreporting/misreporting/no
portion size standard
+/–
Methodology used to estimate high percentiles (95th) long-term (chronic) exposure based on
data from food consumption surveys covering only a few days
+
Correspondence of reported use levels and analytical data to the food items in the EFSA
Comprehensive Database: uncertainties to which types of food the levels refer
+/–
Uncertainty in possible national differences in use levels of food categories +/–
Concentration data:– use levels considered applicable to all foods within the entire food
category, whereas on average 1% of the foods, belonging to food categories with foods
labelled with additive, was labelled with the additive
+
Possible degradation of tartaric acid at high temperatures (e.g. during baking) not considered
in the exposure assessment
+
The 17 food categories included in the refined exposure assessment scenarios out of all
authorised food categories (n = 81) corresponded to 4% to 94% of the amount (g of foods by
body weight) of food consumption documented in the EFSA Comprehensive Database
–
Food categories selected for the exposure assessment: inclusion of food categories without
considering the restriction/exception (n = 2 for all scenarios out of 81 food categories)
+
Maximum level exposure assessment scenario:– exposure calculations based on MPLs and the
maximum reported use levels (reported use from industries)
+
Refined exposure assessment scenarios:– exposure calculations based on the maximum or
mean reported use levels (reported use from industry)
+/–
(a): +, uncertainty with potential to cause overestimation of exposure; –, uncertainty with potential to cause underestimation of
exposure.
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The Panel noted further that the percentage of foods per subcategory labelled to contain tartaric
acid and tartrates (E 334-337 and E 354) was maximally about 20% in the food subcategory Baby
Biscuits & Rusks (78 out of 388 products in total) (Appendix C.1), with an average percentage of 1%
among all subcategories. In the exposure assessment, it was assumed that 100% of the foods
belonging to an authorised food category contained the additive.
Additionally, the possible degradation of tartaric acid at high temperatures (e.g. during baking) was
not considered in the exposure assessment due to the absence of data (Section 3.1.5).
Given these observations, the Panel considered that the uncertainties identified have resulted in an
overestimation of the exposure to tartaric acid and tartrates (E 334-337 and E 354) from their use as
food additives according to Annex II to Regulation N°1333/2008 in European countries considered in
the EFSA Comprehensive Database for all three exposure scenarios.
The Panel noted that food categories which may contain tartaric acid and tartrates (E 334-337 and
E 354) due to carry-over (Annex III, Parts 2, 3, 4, 5A) were not considered in the current exposure
assessment and this may have resulted in an underestimation of the exposure to these additive from
all authorised sources (Annex II and Annex III).
3.4.2. Exposure from natural occurrence
L(+)-Tartaric acid is the primary non-fermentable soluble acid in grapes and the principal acid in
wine. In grapes, the synthesis of tartaric acid starts in the early stages of berry development, resulting
in the accumulation of tartaric acid in their pulp. Furthermore, tartaric acid is present in many other
fruit and vegetables. In some of them, the presence of tartaric acid is the result of L-ascorbic acid
catabolism.
To estimate the exposure to naturally occurring tartaric acid, levels of tartaric acid reported in the
literature were used (Appendix H). Only the exposure via the consumption of wine (FC 14.2.1) and
non-processed fruits and vegetables (corresponding to FC 04.1) was considered:
– For fruits: grapes, berries and pome fruits.
– For vegetables: root vegetables, bulb vegetables, fruiting vegetables, brassica vegetables,
leaf vegetables, stem vegetables and legumes vegetables.
The presence of tartaric acid in wine could come from natural occurrence and from the addition to
wine as a food additive according to Regulation (EU) 934/2019.
For the other products from the diet for which levels of tartaric acid were reported in the literature,
no distinction could be made between added and naturally occurring tartaric acid. These products
were therefore excluded from this exposure assessment (Appendix H).
Table 12 summarises the estimated exposure to tartaric acid from its natural occurrence in the diet.
The mean exposure to tartaric acid ranged from 0.3 mg/kg bw per day in children and adolescents
to 8 mg/kg bw per day in the elderly. The 95th percentile of exposure to tartaric acid ranged from
0.7 mg/kg bw per day in adolescents to 26 mg/kg bw per day in the elderly.
For infants, toddlers and children, the main contributing food category to the total mean exposure
estimates of tartrates from natural sources was unprocessed fruit and vegetables. For the older age
groups, unprocessed fruit and vegetables and alcoholic beverages, including alcohol-free and low-
alcohol counterparts, contributed most to the mean exposure.
Detailed results per population group and survey for the dietary exposure to tartaric acid from its
natural occurrence in the diet are presented in Appendix I.
Table 12: Summary of dietary exposure to tartaric acid from its natural occurrence in the diet, in
six population groups (minimum–maximum across the dietary surveys in mg tartaric acid/
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3.4.3. Exposure to tartaric acid from the use of tartaric acid-tartrates (E 334-
337 and E 354) and related food additives (tartaric acid esters of mono-
and diglycerides of fatty acids (E 472d), mono- and diacetyl tartaric acid
esters of mono- and diglycerides of fatty acids (E 472e), mixed acetic and
tartaric acid esters of mono- and diglycerides of fatty acids (E 472f),
metatartaric acid (E 353) and stearyl tartrate (E 483))
The Panel noted that in addition to the exposure to tartaric acid from the use of tartaric acid and
tartrates (E 334-337 and E 354), tartaric acid can be released from the use of other food additives, i.e.
tartaric acid esters of mono- and diglycerides of fatty acids (E 472d), mono- and diacetyl tartaric acid
esters of mono- and diglycerides of fatty acids (E 472e), mixed acetic and tartaric acid esters of mono-
and diglycerides of fatty acids (E 472f) (EFSA FAF Panel, 2020a), metatartaric acid (E 353) (EFSA FAF
Panel, 2020b) and stearyl tartrate (E 483) (EFSA FAF Panel, 2020c).
The Panel estimated the chronic dietary exposure to tartaric acid from the use of these food
additives. Reported use levels were available for their exposure assessment except for stearyl tartrate
(E 483), which was therefore not considered for this assessment (Appendix J)
Food categories considered for the exposure assessment of tartaric acid
The food categories for which use levels of all food additives releasing tartaric acid were provided
were selected from the nomenclature of the EFSA Comprehensive Database (FoodEx classification
system), at the most detailed level possible (up to FoodEx Level 4) (EFSA, 2011b).
In total 22 food categories were included in the exposure assessment. For four of these categories,
the restrictions/exceptions which apply to the use of food additives releasing tartaric acid could not be
taken into account, and therefore, the whole food category was considered in the exposure assessment.
This applies to four food categories and may have resulted in an overestimation of the exposure:
• 05.1 Cocoa and chocolate products as covered by Directive 2000/36/EC, only energy-reduced
or with no added sugar. The whole food category was taken into account as it is not possible
to separate energy-reduced or with no added sugar cocoa and chocolate products from regular
cocoa and chocolate products;
• 07.1 Bread and rolls, except products in 7.1.1 and 7.1.2. The whole food category was taken
into account as it is not possible to exclude products belonging to FCs 7.1.1 and 7.1.2;
• 13.1.3 Processed cereal-based foods and baby foods for infants and young children as defined
by Directive 2006/125/EC, only biscuits and rusks and baby foods. The whole food category
was considered as it is not possible to only select biscuits and rusks and baby foods;
• 14.1.5.2 Other (i.e. chicory extracts, tea, herbal- and fruit-infusions; coffee substitutes, coffee
mixes and mixes for ‘hot beverages’), excluding unflavoured leaf tea; including flavoured
instant coffee.
Exposure estimates
To estimate the exposure to tartaric acid, the amount of tartaric acid released from the different
additives needs to be established. The Panel used for this the total amount of tartaric acid in the
additives (% by weight) according to the EU specifications for these food additives (Commission
Regulation (EU) No 231/2012). According to these specifications, E 472d contains maximally 40%,
E 472e and E 472f maximally 50% and E 483 maximally 40% tartaric acid. Metatartaric acid (E 353)
was assumed to be hydrolysed to an approximately equivalent amount of tartaric acid (EFSA FAF
Panel, XX). The Panel used these released amounts as the maximum release on which exposure to
tartaric acid was estimated.
The different additives considered in this exposure assessment have different functions in foods
and can therefore be used together in the same food. For instance, metatartaric acid (E 353) is used
to avoid the precipitation of tartaric acid (E 334) so both can be used together.
Considering the above, the use levels provided for each food additive and food category (or a
percentage of these levels depending of the hydrolysis of the food additive into tartaric acid) were
summed to get a total ‘potential’ concentration of tartaric acid in all foods within a food category.
These levels were then used to estimate the chronic dietary exposure to tartaric acid.
Dietary exposure to tartaric acid was calculated as described in Section 3.4.1. Added to the
uncertainties described in Table 11, estimates are based on the maximum possible amount of tartaric
acid released from the other food additives and all food additives were considered present together in
the same food.
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Detailed results per population group and survey are presented in Appendix K. For the actual
contributions per population group and food categories, see Appendix L.
Table 13 summarises the estimated exposure to tartaric acid from the use of E 472d, E 472e, E
472f, tartaric acid and tartrates (E 334-337 and E 354) and metatartaric acid (E 353) as food additives
in the non-brand loyal refined exposure scenario.
Mean exposure to tartaric acid from the use of several food additives ranged from 2 mg/kg bw per
day in infants to 127 mg/kg bw per day in toddlers. The 95th percentile of exposure ranged from
7 mg/kg bw per day in infants to 278 mg/kg bw per day in toddlers.
Compared to the mean dietary exposure to only tartaric acid and tartrates (E 334-337 and E 354)
from their use as food additives, mean estimates including all food additives releasing tartaric acid are
higher by a factor of approximately 1.3 up to 2 among the populations.
FC 07.1 Bread and rolls was the major contributor to the mean exposure in all scenarios and
population groups except infants for whom the major contributor was FC 13.1.3 Processed cereal-based
foods and baby foods for infants and young children. The 2nd food category that contributed significantly
to the exposure in toddlers, children, adolescents and adults was FC 14.1.4 Flavoured drinks.
Exposure to tartaric acid from the use of several additives is an overestimation, due to the
uncertainties described for tartaric acid and tartrates (E 334-337 and E 354) (Table 11). Additionally,
for the food categories for which there were reported use levels for more than one food additive, it
was assumed that these food additives were present together in the same food while the information
from the Mintel GNPD indicated that this is not frequently the case.
When the total exposure to tartaric acid from all sources of food additives and natural sources is
calculated using the methodology described in Section 3.4.1, the mean exposure ranged from 2 mg/kg
bw per day in infants to 130 mg/kg bw per day in toddlers. The 95th percentile of exposure ranged
from 8 mg/kg bw per day in infants to 285 mg/kg bw per day in toddlers. Taking into account the
uncertainties described above, this exposure estimate is also an overestimation.
3.5. Biological and Toxicological data
The Panel considered that sodium, potassium and calcium salts of tartaric acid are expected to
dissociate in the gastrointestinal tract into tartrate and their corresponding cations. The resulting
sodium, potassium and calcium cations will enter their normal physiological processes. The toxicity of
the corresponding cations was therefore not addressed in the opinion.
3.5.1. Absorption, distribution, metabolism and excretion
Although only the L(+)-form of tartaric acid and tartrates is authorised as a food additive in the EU,
when in some studies the racemic (DL-form) or the D(-)-form were used for comparison with the L(+)-
form, these data have also been reported in this opinion.
In vitro studies
Chadwick et al. (1978) studied the metabolism of sodium D(-)- and L(+)-tartrate in a faecal
incubation system. Sodium D(-)- or L(+)-tartrate (30 mL of 250 mmol/L) was incubated anaerobically at
37°C for 24 h with fresh faeces from five healthy subjects. Tartrate was measured at 0, 3, 6, 7.5 and
24 h. The percentages ( SEM) of tartrate still present in the samples were 45  13, 32  14 and
< 25% for L(+)-tartrate after 3, 6 and 7.5–24 h, respectively; and 91  7, 87  9, 64  8
and 34  16% for D(-)-tartrate after 3, 6, 7.5 and 24 h, respectively (due to the insensitivity of the
method used for analysis of tartrate, it was not possible to accurately measure tartrate concentrations
Table 13: Summary of dietary exposure to tartaric acid from the use of E 472d, E 472e, E 472f,
tartaric acid and tartrates (E 334-337 and E 354) and metatartaric acid (E 353) as food
additives in the non-brand loyal refined exposure scenario, in six population groups
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below 25% of the initial dose). When tartrate concentrations were plotted logarithmically against time,
50% loss was recorded after approximately 4 h for L(+)-tartrate and 20 h for D-tartrate indicating that
the natural isomer L(+)-tartrate was metabolised five times more rapidly than the D-tartrate.
The metabolism of DL-[1,4-14C]tartrate by intestinal bacteria was also investigated in the same
study by Chadwick et al. (1978). Pure cultures of aerobic (Enterobacteria, Enterococci, Micrococci and
Bacillus sp.) and anaerobic (Clostridia, gram-positive non-sporing bacilli and gram-negative non-sporing
bacilli) bacteria were incubated anaerobically for 48 h at 37°C with 0.1 lCi of DL-[1,4-14C]tartrate/mL.
The percentages of metabolised tartrate (mean  SD) were 36.5  20.2, 15.7  13.6, 12.5  8.9 and
7.1% after incubation with Enterobacteria, Enterococci, Micrococci and Bacillus sp., respectively. The
percentages of metabolised tartrate (mean  SD) were 18.5  6.5, 7.5  7 and 4  3.9 after incubation
with Clostridia, gram-positive non-sporing bacilli and gram-negative non-sporing bacilli, respectively. On
several occasions more than 50% of the radioisotopic label was converted into CO2, showing, according




Sourkes and Koppanyi (1950) compared the rate of excretion of tartaric acid in dogs gavaged with
500 mg tartaric acid/kg (in water) and given either as tartaric acid (n = 2) or tartaric acid esters of
mixed mono- and diglycerides (n = 4). Twelve hours after administration of tartaric acid, up to 60% of
the administered dose was found in urine, whereas only 6–18% was found in animals receiving tartaric
acid esters of mixed mono- and diglycerides. The rapid and large excretion of tartaric acid in dogs
receiving this compound was associated with histopathological nephrotic changes, which were not found
in animals receiving tartaric acid esters of mixed mono- and diglycerides. The authors concluded that the
toxicity of tartaric acid was correlated with a high rate of renal excretion whereas tartaric acid esters of
mixed mono- and diglycerides, which is well absorbed but slowly excreted showed no renal toxicity.
Fasted Wistar rats (5 animals/sex), guinea pigs (11 females) and Danish Landrace pigs (3 females)
were given 1,000, 1,000 and 500 mg/kg bw, respectively, of L(+)-tartaric acid by gavage (Gry and
Larsen, 1978). The percentages of L(+)-tartaric acid recovered in urine after 48 h were (mean  SD):
72.9  15.7, 3.6  3.1 and 26 (17–43) (mean (range)), for the rats, guinea pigs and pigs,
respectively. In addition, L(+)-tartaric acid was incubated at concentrations of 10 mg/mL for up to 24 h
in caecal extracts from either rat or guinea pig and there were no differences in the ability to
metabolise L(+)-tartaric acid between the species. The authors also looked at the excretion of D-tartaric
acid administered to the animals under the same conditions. The rats had a lower recovery in urine of
the D(-)-form compared to the L(+)-form (52% and 73%, respectively). The authors noted that: ‘the
low recovery of both isomers in guinea pigs was associated with marked kidney damage while this
effect was not found in the rat after administration of the L(+)-form’ and considered that ‘some
correlation exists between low recovery of unchanged tartrate in urine, which reflects some absorption
in the small intestine, and kidney damage’. The authors considered that the percentage recovery in the
urine of pigs (26%) is close to the one reported for humans (20%).
Potassium tartrate
Male Wistar rats (8 animals/group, 6 weeks old, weighing ca. 180 g) were given for 21 days
potassium tartrate (stereoisomeric composition not specified) at a concentration of 47.9 g/kg diet, or
a control diet (Sabboh et al., 2007). During the last 4 days of the experiment, the feed intake was
determined and urine was collected and analysed for tartrate. Mean (SEM) feed intake was 17.31 (0.79)
and 17.65 (0.62) g/day in the potassium tartrate and control group, respectively. Mean (SEM) urinary
excretion of tartrate was 2.2 (0.25) mmol/24 h in the potassium tartrate group, which was reported by
the authors to correspond approximately to 50% of the tartrate intake. Caecum content of tartrate was
4.7 mmol/g. Caecum content was analysed for acetate, propionate, butyrate, lactate and succinate.
Sodium tartrate
In a study investigating the absorption and biotransformation of monosodium L(+)-tartrate,
adult Sprague-Dawley CFY rats (3 males and 3 females, weighing 200–250 g) were dosed by gavage
with monosodium 14C-L(+)-tartrate at a dose level of 400 mg/kg bw in water (Chasseaud et al., 1977).
Urine, faeces and expired air (14CO2) were collected and the rats were sacrificed after 2 days.
Excretion of radioactivity was almost completed within 12 h and in the expired air within 24 h. At 48 h
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after dosing, 70.1  4.1%, 13.6  7.3% and 15.6  2.7% had been excreted in the urine, faeces and
expired air, respectively, indicating that L(+)-tartrate was extensively absorbed and that a part was
metabolised to carbon dioxide.
In a study with the purpose of investigating the renal and bone uptake of monosodium L(+)-
tartrate, a total of 10 male Sprague Dawley CFY rats (weighing 160–180 g) were given by gavage
2,730 mg/kg bw per day monosodium L(+)-[14C] tartrate for 7 days (Down et al., 1977). One animal
was sacrificed immediately before the 7th day’s dose and the remaining animals were sacrificed at
intervals during the following 12 days. Blood was sampled immediately before sacrifice. Carcasses were
subjected to whole-body autoradiography and the nature of radioactivity in bone was determined.
Radioactivity was observed in whole-blood, plasma, bone and kidneys. Peak concentrations (lg
equivalents of L(+)-tartaric acid) of radioactivity were 176 lg/mL, 279 lg/mL, 787 lg/g and 3,983 lg/g,
respectively, 1 h after the 7th dose. After 12 days concentrations had declined to 23 lg/mL, 2 lg/mL,
208 lg/g and 38 lg/g, respectively. The radioactivity in plasma declined biophysically with half-lives of
about 3 and 53 h after the last dose. Localisation of radioactivity in bone persisted for at least 8 days
after the last dose. The amount of radioactivity in bone was estimated to be 0.4% of the total
administered dose, whereas the L(+)-form was not retained in the kidney. On the contrary, in animals
that had received the same dose of calcium DL-tartrate, retention of this DL-form was observed in the
kidney. According to the authors, this was due to the DL-form being less soluble than the L(+)-form and
could be a possible explanation for the higher nephrotoxic effect of the DL-form as compared to the L(+)-
form.
In the Chadwick et al. (1978) study, rats (200–250 g) were given by gavage 20 lCi of sodium DL-
[1,4-14C]tartrate (with 18.8 mg/kg L(+)-tartrate as carrier). The specific radioactivity of labelled CO2
in breath was measured every 30 minutes for 6 h and urinary excretion of [14C]tartrate was measured
over 24 h; faeces were not collected. The recovery of 14CO2 in expired air and [
14C]tartrate in urine
was (mean  SEM) 21.8  1.4 and 51.0  4.5%. Absorption of tartrate from the intestine was
calculated as 81% of the dose; urinary radioactivity amounted to 70% with the difference between
absorption and urinary excretion representing metabolism in body tissues.
Potassium sodium tartrate
Underhill et al. (1931a) reported on the metabolism of potassium sodium L(+)-tartrate
(Rochelle salt) in rats, guinea pigs and dogs administered by gavage or subcutaneously; rabbits were
administered by gavage or intramuscularly. Tartrate was determined in the urine by a colorimetric
method. According to the authors, the guinea pig was unique among the laboratory animals examined
as only a small portion (16%) of the tartrate reappeared in the urine when administered by gavage,
and tartrate could not be detected in the faeces. They also concluded that during its passage in the
gastrointestinal tract of the guinea pig, tartrate was altered (oxidised?) so that it no longer responded
to the tartrate test. This was supported by the observation that 96–100% of the administered dose of
tartrate was recovered in urine when it was injected subcutaneously to the guinea pigs. Such a change
in the percentage of tartrate recovered in urine was not observed under the same conditions in rats,
dogs and rabbits. In addition, the authors reported that the dog was more resistant to the
nephropathic action of tartrate (depression of renal function as assessed by the phenolsulfonphthalein
test, and renal necrosis at doses above 200 mg/kg bw), than the rabbit (see also Section 3.4.2).
Human studies
A total of four subjects (two young men and two young women) were given diets supplemented
with L(+)-tartaric acid or potassium sodium tartrate (Rochelle salt) (Underhill et al., 1931b).
Urine and faeces were collected in 24-h periods. After 7.8–9.4 g of L(+)-tartaric acid, the urinary
recovery was between 12 and 18.7%. After 10 g of potassium sodium tartrate (corresponding to 5.3 g
tartaric acid), the urinary recovery ranged between 12.8 and 15.4%. No trace of tartrate was present
in the faeces. The dosing was repeated in six subjects (two young men and two young women) but
with a smaller quantity of tartrate. Here the amount of L(+)-tartaric acid ingested was between 2.3 and
4.5 g and the urinary recovery was between 8.7 and 20.4%. The amount of tartaric acid ingested
from potassium sodium tartrate was 5.3 g (as in the first dosing), but the urinary recovery ranged
between 2.4 and 5%. An additional study with 2 men showed no recovery of L(+)-tartaric acid in urine
less than 10 h after ingestion of 2.5 g L(+)-tartaric acid. To investigate the fate of L(+)-tartaric acid in
the gastrointestinal tract, fresh faeces were diluted with water and mixed with 20 mg of L(+)-tartaric
acid, L(+)-tartaric acid neutralised or potassium sodium tartrate. Samples were subsequently kept at
37.5°C or 0°C for up to 8 h. After 8 h of incubation with L(+)-tartaric acid, the amount of recovered L
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(+)-tartaric acid was 0 and 10–12 mg after 37.5 and 0 °C, respectively. When potassium sodium
tartrate was incubated with faeces at 37.5°C for 4 h the recovery of L(+)-tartaric acid was 0 mg, but
10 mg after incubation for 6 h at 0°C. After 4 h of incubation with potassium sodium tartrate, the
amount of recovered L(+)-tartaric acid was 0 after 37.5°C. In addition, L(+)-tartaric acid was incubated
at 37.5°C with intestinal contents obtained through a fistula in the caecum. After 4.5, 7.5, 10.5 and
24 h, the decomposition of L(+)-tartaric acid was 0, 23.5, 73.5 and 100%, respectively.
A group of 12 men were given 2 g ‘D-tartaric acid’ as sodium tartrate in two capsules of 1 g
each, and allowed to drink as much water as desired. Urine was collected for a minimum of 12 h
(Finkle, 1933). Recovery of tartrate in urine ranged from 11.5 to 24.7% with an average of 17.4%
after oral administration. In another group of 10 individuals receiving sodium tartrate by intramuscular
injection (1 g), tartrate was almost completely recovered in the urine within 12 h. The authors
concluded that: ‘with the low doses employed in our observations on human beings, renal damage did
not occur, and it is therefore possible to recover practically all of the injected tartrate in the urine and
to demonstrate that none of this fruit acid is utilised by human beings’.
After ingestion of sodium L(+)-tartrate (2 g expressed as tartaric acid, repeated on four
occasions, 1 week apart), between 0.4 and 12.2% L(+)-tartaric acid was recovered in the urine
(collected for a minimum of 12 h) in a single subject (Bauer and Pearson, 1957). It was reported that
L(+)-tartaric acid was metabolised when given in small amounts by per-oral administration, as well as
by intramuscular injection (ca. 750 mg). The same conclusion was reach with D(-)- and DL-tartrates.
Two subjects (A and B, gender not specified) were given sodium L(+)-tartrate in three oral doses
of a total of 1.5 mmol/kg per day (corresponding to 346 mg tartaric acid/kg bw per day) for 2 (subject
A) or 4 (subject B) days (Chadwick et al., 1978). Excreted tartrate was measured in urine from subject B
and hydrogen ion excretion and pH were measured in urine from both subjects. These analyses were
also performed on several days before and after the dosing. Subject B was on a constant diet. Subjects
A and B received a daily total of 130.5 and 104.5 mmol sodium L(+)-tartrate (corresponding to 30 and
24 g sodium L(+)-tartrate, respectively, calculated on the basis of the molecular weight of disodium
tartrate (230.8 g/mol)). Urinary pH from subject A was 5.8 before and 7.69 after the dosing and similar
from subject B. Urinary tartrate excretion from subject B was between 8.9 and 10.3 mmol during the
dosing period equivalent to 7.4% of the total administered dose.
In the same study by Chadwick et al. (1978), five healthy human subjects (28–45 years old) were
given 5 lCi of sodium DL-[1,4-14C]tartrate (with sodium L(+)-tartrate as carrier) in three different
doses: 2.5, 5 or 10 g. The specific radioactivity of labelled CO2 in breath and urinary [
14C]tartrate
excretion was measured every hour for 7 h. Stools were weighed and analysed immediately after they
were passed. There were no differences in percentages of excreted 14C between the doses, so the
results from all five subjects were pooled. The percentage recovery of 14C (mean  SEM) of the
administered dose was 46.2  8.1, 12  1.2 and 4.9  1.7% in the breath, urine and faeces,
respectively. The concentration of 14CO2 in expired air peaked after 4 h consistent with, according to
the authors, the time for sodium DL -[1,4-14C]tartrate to reach the colon and be exposed to colonic
bacteria. The concentration of [14C]tartrate in urine peaked 1–2 h after ingestion of sodium
DL-[1,4-14C]tartrate. A single subject received 10 lCi of DL-[1,4-14C]tartrate intravenously (with 125 mg
sodium L(+)-tartrate as carrier). The specific radioactivity of labelled CO2 in breath and urinary
[14C]tartrate excretion was measured every hour for 8 h. The percentage recovery of 14C of the
injected dose was 18 and 63.8% in the breath and urine, respectively. The concentration of 14CO2 in
expired air peaked after 1 h suggesting, according to the authors, a rapid metabolism by tissue
enzymes. From the differences in the urinary excretion of labelled tartrate after oral and parenteral
administration, absorption of tartrate from the intestine was calculated as 18% of the dose and urinary
radioactivity amounted to 14% of the dose.
Thirteen healthy subjects (seven males and six females; 27–65 years of age) were fed 5 g cream of
tartar (monopotassium tartrate) or 120 g sun dried raisin, both equal to approximately 2 g tartaric acid,
per day for 9 weeks, divided into 3-week cycles (Spiller et al., 2003). The experimental diets were fed in
a crossover design after an initial control period. Faeces were collected for the last 4 days of each cycle
for analysis of Short Chain Fatty Acids (SCFA). The authors indicated that tartaric acid was fermented by
colonic bacteria, which utilise it for the production of SCFA, the concentration of faecal SCFA remained
unchanged during the study, which is likely indicative of an absorption of SCFA in the colon.
Overall, the metabolism of L(+)-tartaric acid and its potassium sodium salt was shown to be species-
dependent. In rats, after oral administration, up to 81% of labelled tartrate was absorbed (Underhill
et al., 1931a; Chadwick et al., 1978; Gry and Larsen, 1978). In rats, L(+) and D(-)-tartrate were excreted
differently in urine after gavage, the L(+)-form being more efficiently excreted than the D(-)-form (Gry
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and Larsen, 1978). Up to 10% of labelled parenteral tartrate was expired as CO2 within 6 h and 63% was
found in the urine over 24 h, which indicated significant metabolism by tissues (Chadwick et al., 1978).
High rate of renal excretion (up to 60% within 12 h) was reported in dogs receiving tartaric acid (Sourkes
and Koppanyi, 1950). Underhill et al. (1931a) found that after parenteral injection of tartrate, recovery
ranged from 70% in rabbits, dogs and rats to almost 100% in guinea pigs. Therefore, tissue metabolism
could not be excluded in these species; however, it played a minor role in disposal of tartrate.
In man, only 12% of tartrate administered orally appeared in the urine; as this was unrelated to
dose absorption was likely passive (Chadwick et al., 1978). The difference in urinary excretion after an
oral dose (12%) or an intravenous dose (66%) suggested that only a fraction of the oral dose was
systemically available (approximately 18% according to Chadwick et al., 1978). Finkle (1933) found
that 91% of an intramuscular dose of unlabelled tartrate was recovered in the urine, which according
to the authors, indicated that the human body cannot metabolise tartrate. It must be noted, however,
that in the intramuscular part of the study, D-tartrate was most probably used because the author
described D-tartrate in the oral part of the study. After an intravenous injection of 14C-L-tartrate,
Chadwick et al. (1978) reported that 66% of the radioactivity was excreted in the urine in 22 h, and
that 18% was excreted as 14CO2 over 8 h. The concentration of
14CO2 in expired air peaked after 1 h
and contained 7% of the dose suggesting, a rapid metabolism by tissue enzymes. The
Panel considered that the different recoveries of 91 and 66% may be due to the different
stereospecific forms. However, these recoveries are not directly comparable because radioactivity was
measured in one study while unlabelled tartrate was analysed in the other study. Tartrate was
fermented by colonic bacteria, with L(+)-tartrate being metabolised faster than D(-)-tartrate (Chadwick
et al., 1978). Spiller et al. (2003) reported that tartaric acid/tartrate were fermented by colonic
bacteria to SCFAs, which then can be absorbed in the colon.
The Panel noted that no information on the ADME of calcium tartrate was available.
3.5.2. Acute toxicity
Mice
Mice (reported to be white, of mixed strain and sex, average weight 22–23 g) were administered by
gavage with a single dose of a 25% solution in water of disodium tartrate (stereoisomeric composition
not specified) in doses of 12 (30 animals), 20 (35 animals) or 30 (51 animals) mmol/kg (corresponding to
2,770, 4,616 or 6,924 mg/kg bw, respectively). An LD10 was established at 4,385 mg/kg bw (Locke
et al., 1942).
Rabbits
Fasting rabbits (1–5 males/group) were orally administered potassium sodium tartrate or
tartaric acid (stereoisomeric composition not specified) in single doses corresponding to 26–300 mg/kg
bw of tartaric acid (Underhill et al., 1931a). According to the authors, renal performance was assessed
by the phenolsulfonphthalein test before and after administration and nitrogen was measured in urine.
The animals were killed and the kidneys were examined histologically 3–4 days after administration.
Diarrhoea was observed in animals given the highest dose of potassium sodium tartrate (300 mg/kg as
tartaric acid). The renal performance test showed decreased kidney function at all doses. Changes in
urinary nitrogen were not associated with kidney injury.
Rabbits (New Zealand White males) were administered by gavage with a single dose of a 25%
solution in water of disodium tartrate (stereoisomeric composition not specified). Three out of seven
rabbits died after an average oral dose of 5,308 mg tartaric acid/kg bw, while six out of six rabbits
survived an average dose of 3,693 mg tartaric acid/kg bw (Locke et al., 1942).
Dogs
Fasting dogs (1–4 animals/group (sex unspecified)) were gavaged with single doses of 100, 200,
400, 600, 1,000, 1,500 or 2,000 mg/kg bw tartaric acid given as potassium sodium tartrate
(stereoisomeric composition not specified) (Underhill et al., 1931a). The animals were killed 3 days
after and kidney sections were examined microscopically. According to the authors, renal performance
was assessed by the phenolsulfonphthalein test before and after the administration. Diarrhoea and
slight to medium (highest dose only) renal changes (not further specified) were observed in dogs
given tartaric acid as potassium sodium tartrate in doses of 400–2,000 mg/kg bw. Renal tests showed
decreased kidney function at doses of 600–2,000 mg/kg bw.
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Overall, only outdated studies were available, they reported that disodium tartrate has a low acute
toxicity in mice. Impaired kidney function was observed in rabbits and dogs after a single oral dose of
potassium sodium tartrate higher than 50 and 600 mg/kg bw, respectively, and renal changes were
observed in dogs at doses above 400 mg/kg bw.
3.5.3. Short-term and subchronic toxicity
Rats
A total of 10 male CFY rats (weighing 160-180 g) were given 2,730 mg/kg bw per day
monosodium L(+)-[14C] tartrate for 7 days by gavage. One animal was sacrificed immediately
before the 7th day’s dose and the remaining animals were sacrificed at intervals during the following
12 days (Down et al., 1977). Liver and kidneys were weighed and examined macroscopically. No
adverse effects were observed. In the same study, the authors reported that when DL-form was
administered under the same conditions, the liver of the animals was not affected; however, kidneys
had changes consistent with crystalluria. Main findings were focal chronic and mixed inflammation of
the interstitium and small number of tubules containing birefringent crystals.
In the Inoue et al. (2015) study, groups (n = 10) of male and female F344/DuCrj rats were fed for
90 days a diet containing 0, 0.125%, 0.5% and 2% monopotassium DL -tartrate (equivalent to 0,
75, 150 and 600 mg/kg bw per day expressed as potassium hydrogen DL-tartrate or approximately to
0, 60, 120 and 480 mg/kg bw per day if expressed as tartaric acid). The study was conducted in
accordance with official Japanese Test Guidelines and GLP. The test compound was described by the
authors as a mixture containing equal amounts of D(-)- and L(+)- monopotassium tartrate, plus small
amounts of mesotartaric acids. Microscopic findings were irregular dilation of the distal tubule lumen,
foreign body giant cells, inflammatory cell infiltration. Regeneration of renal tubules was observed in
the renal cortex and/or medulla in the 0.5% and higher dose groups. The severity of these lesions was
dose dependent. In urine, an increase in protein and white blood cells together with the concentration
of tartaric acid was found from the 0.5% dosage groups of both sexes. However, blood biochemical
analysis did not indicate any failure of renal function. No other treatment-related changes in other
organs were reported. According to the authors, these results indicated that the monopotassium
DL-tartrate induced obstructive nephropathy in rats. The Panel identified an NOAEL of 0.125% in the
diet (equal to 75 mg and 82 mg monopotassium DL-tartrate/kg bw per day, or to 60 and 68 mg
DL-tartaric acid/kg bw per day, in males and females, respectively).
The Panel noted that the authors (Inoue et al., 2015) stated that the tested compound
(monopotassium DL-tartrate) is registered as a food additive, however, in the EU, only the L(+)-form of
monopotassium tartrate (E 335 (i)) is authorised as a food additive.
Rabbits
Male rabbits (n = 15) were fed 0 or 7.7% sodium tartrate (stereoisomeric composition not
specified) in their diet for up to 150 days (Packman et al., 1963). Food consumption and mean body
weights were recorded at 4, 8, 16 and 22 weeks, the calculated intake was approximately 550 mg/kg
bw per day. After 60 days, blood samples from five treated animals and six control animals were
examined (erythrocyte, leucocyte and differential leucocyte counts, blood sugar and non-protein
nitrogen determinations). Urine samples from an equal number of animals were also examined (colour,
appearance, specific gravity, sugar, albumin, alkalinity and microscopic constituents). After 30 days
(2 animals from each group) and 60 days (1 animal from each group), gross pathological examinations
were performed, organs (adrenals, bladder, brain, heart, kidneys, liver, lung, prostate, spleen, stomach,
testes and thyroid) were weighed and testes were examined histologically. After 100 days, similar
examinations were performed on one-half of the surviving animals of each group, as well as histological
examination of the liver and kidney. After 150 days, all surviving animals were sacrificed and examined
macroscopically and microscopically. No treatment-related adverse effects were observed.
Dogs
Four dogs were given a daily oral dose of 990 mg/kg bw (in two gelatine capsules about 6 h apart)
of tartaric acid (stereoisomeric composition not specified) for a period of 90–114 days (Krop and
Gold, 1945). The general appearance and behaviour of dogs were observed during the entire
experiment. Weight was measured and urine and blood were collected on a weekly basis. Urine was
analysed for specific gravity, pH, albumin and blood cells. Blood was analysed for non-protein nitrogen
(NPN) and creatinine. At 3-week intervals, the serum CO2 combining power and kidney function were
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determined. Tests were carried out more frequently in dogs showing signs of poisoning. All animals
underwent gross post-mortem examinations and liver, kidney and lung tissue from 1 dog was prepared
for histological examination. Weight changes varied from a gain of 30% to a loss of 32%. Casts
appeared in the urine from 3 dogs after 19, 38 and 89 days, respectively. No changes in the measured
parameters were observed except in one dog, which had increased blood NPN, creatinine and albumin
(azotemia) after 88 days and died after 90 days. Histopathological examination showed advanced
tubular degeneration of the kidney. No other adverse effects were observed.
Overall, no adverse effects were observed in rats given 2,730 monosodium L-tartrate/kg bw per
day. In the same study, DL-tartaric acid was shown to cause kidney effects. Furthermore, in a 90-day
study in rats, an NOAEL of 60 mg/kg bw per day was identified for monopotassium DL-tartrate, based
on kidney histological alterations (obstructive nephropathy) reported at higher doses.
In rabbits given 550 mg monosodium tartrate/kg bw per day acid (stereoisomeric composition not
specified), no adverse effects were observed. Advanced tubular degeneration of the kidneys and
increased blood NPN, creatinine and albumin were observed in one out of the four dogs given
990 mg/kg bw per day tartaric acid (stereoisomeric composition not specified), the only dose tested.
The Panel considered that the renal effects reported with tartrates were most likely due to the
presence of the D-form of tartaric acid only.
3.5.4. Genotoxicity
In vitro
L(+)-tartaric acid, monosodium tartrate and monopotassium tartrate (stereo-isomeric composition
not specified) (purity 99.0, 99.5 and 100.0%, respectively) were tested in the Salmonella/microsome
test using Salmonella typhimurium strains TA 92, TA 94, TA 98, TA 100, TA 1535 and TA 1537 (with
and without metabolic activation) in the pre-incubation assay. All three substances were reported to be
negative in the Salmonella/microsome test (Ishidate et al., 1984). The Panel noted that the reliability
of this study was limited (the bacterial strains TA102 or E. coli WP2 were not used, the substances
were tested only on duplicate plates, and the results were not reported in detail since the publication
is a compilation of results obtained with many substances).
Potassium sodium tartrate (purity not reported; stereoisomer not reported but based on the
reported CAS Number (304-59-6) the test material was potassium sodium L(+)-tartrate) was tested for
mutagenicity in the Salmonella/microsome test using Salmonella typhimurium strains TA 98, TA 100,
TA 1535 and TA 1537 (with and without metabolic activation) and in Escherichia coli strain WP2 in the
plate-incorporation assay in concentrations up to 10 mg/plate. Potassium sodium tartrate was reported
to be negative in both tests. In one experiment, unusual high numbers of histidine revertants were
observed with strains TA1535 and TA100. According to the authors, this was due to an excessive
amount of ethylene oxide used by the manufacturer in the sterilisation of the Petri plates. In a
subsequent experiment performed with these strains, no such unusually high numbers of revertants
were observed (Simons and Eckford, 1979; Prival et al., 1991). The Panel noted that the reliability of
this study was limited (the substance was tested only in duplicate plates, historical control values were
not reported, and unusually high numbers of revertants were observed with strains TA1535 and TA100
in one out of two experiments
L(+)-tartaric acid (purity not reported) was tested for mutagenicity in the Salmonella/microsome
test using Salmonella typhimurium strains TA 97a, TA 98, TA 100 and TA 102 (with and without
metabolic activation) in the plate-incorporation assay in concentrations up to 5 mg/plate (CMBEC, 2004
(Documentation provided to EFSA No. 1)). L(+)-tartaric acid did not induce mutagenicity in this assay.
The Panel noted that this study was mainly consistent with the OECD guideline 471 (except that strain
TA 1535 was not used and purity, individual plate counts, signs of toxicity and historical control data
were not reported). The study can be considered reliable with limitations.
L(+)-tartaric acid, monosodium tartrate and monopotassium tartrate (stereoisomeric composition
not specified) (purity 99.0, 99.5 and 100.0%, respectively) were tested in the in vitro chromosomal
aberration test using a Chinese hamster fibroblast cell line (without metabolic activation) at
concentrations up to 1.0, 15.0 and 2.0 mg/mL, respectively (the mid and low concentrations were not
reported) (Ishidate et al., 1984). L(+)-tartaric acid and monopotassium tartrate were reported to be
negative. Monosodium tartrate was reported to be positive. The Panel noted that this could be due to
the high concentration used which exceeded the recommended maximum concentration (2 mg/L)
according to the OECD Guideline 473. The Panel considered that the reliability of this study was limited
(gaps were not excluded from the evaluation, different types of chromosomal aberrations were not
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reported separately, only 100 metaphases were analysed per concentration, the substances were
tested only in the absence of metabolic activation, and the results were not reported in detail since the
publication is a compilation of results obtained with many substances).
In vivo
L(+)-tartaric acid (purity not reported) was tested in the bone marrow micronucleus assay at doses of
0, 598, 1,075 and 2,150 mg/kg bw in male mice and 0, 395, 790 and 1,580 mg/kg bw in female ICR
mice (five animals per group) (CMBEC, 2004 (Documentation provided to EFSA No. 2)). It was given by
gavage twice with 24-h interval. The mice were sacrificed 6 h after the second gavage. The frequency of
micronucleated cells was analysed in 1,000 polychromatic erythrocytes per animal and the proportion of
immature among total erythrocytes was analysed by counting 200 PCEs and all NCEs. No obvious toxic
effects were observed and the PCE/NCE ratio was not changed. No statistically significant differences in
the frequency of micronucleated cells were observed in the treated groups compared to the negative
control groups. The Panel noted that the study deviated from the current OECD guideline 474
concerning the sampling time and the number of erythrocytes analysed. Additionally, there was no
indication for exposure of the bone marrow. Therefore, the reliability of this study was limited.
L(+)-tartaric acid (purity not reported) was tested for induction of chromosomal aberrations in
primary spermatocytes in male ICR mice at doses of 0, 598, 1,075 and 2,150 mg/kg bw (five animals
per group) (CMBEC, 2004 (Documentation provided to EFSA No. 1)). The test item was given by
gavage once a day, for five consecutive days. A colchicine solution (4 mL/kg bw, concentration not
reported) was injected 6 h before sacrifice. The mice were sacrificed on the 12th day of the
experiment, the spermatocytes were isolated from testes and prepared and stained for microscopic
investigation (stain and conditions of preparation not reported). The frequency of chromosomal
aberrations was analysed in 100 cells per animal. No statistically significant differences in the
frequency of ‘cell aberration’ were observed in the treated groups compared to the negative control
groups. The Panel noted that the study deviated from the current OECD guideline 483 with respect to
the study design (treatment schedule and sampling time), the number of cells analysed and the
reporting (e.g. it is unclear if the result is expressed as chromosomal aberrations per cell or as
percentage of cells bearing chromosomal aberrations; the types of chromosomal aberrations were not
reported, unclear if gaps were excluded). Therefore, the reliability of this study is insufficient.
In silico analysis using the OECD QSAR Toolbox (version 4.2) revealed one structural alert for
in vivo micronucleus induction (‘Hacceptor-path3-Hacceptor’) for tartaric acid and the three tartrates,
while no structural alerts were revealed for DNA binding, protein binding, carcinogenicity, ‘DNA alerts
for Ames by OASIS’ and ‘DNA alerts for CA and MNT by OASIS’. The ‘Hacceptor-path3-Hacceptor’ alert
is an indicator for non-covalent substance/DNA interactions such as intercalation (Snyder et al., 2006).
It is, however, noted by Snyder et al. (2006) that DNA intercalation in the absence of covalent addition
is not necessarily a genotoxic event. Moreover, according to Benigni et al. (2010), the positive
predictivity (i.e. probability for a substance with structural alert to result in a positive experimental
outcome) of this structural alert for the in vivo micronucleus assay is only low (34%).
Overall, L(+)-tartaric acid, monosodium, monopotassium and potassium sodium tartrates did not
show a mutagenic potential in several strains of Salmonella typhimurium and Escherichia coli. The
Panel noted that all studies had shortcomings, however, considering the available data in a weight of
evidence approach, there was no concern for these compounds with respect to a potential for
induction of gene mutations. Concerning structural and numerical chromosome aberrations, there are
no reliable in vitro data available and one in vivo study was of limited reliability. However, based on
these data, there was at least no indication for structural or numerical chromosomal aberrations.
Taking also into account that tartaric acid and tartrates do not have a structural alert that would have
to be regarded as highly predictive for genotoxicity, the Panel considered that there is no concern for
genotoxicity for tartaric acid and its sodium and potassium salts.
3.5.5. Chronic toxicity and carcinogenicity
Rats
Weanling Osborne-Mendel rats (21 days old, 12 animals/sex/group) were given a diet containing 0,
0.1, 0.5, 0.8 or 1.2% tartaric acid (stereoisomeric composition not specified) (equivalent to 0, 50,
250, 400 and 600 mg/kg bw per day) for 2 years (Fitzhugh and Nelson, 1947). A group of 48 animals
was used as control. Weight and feed consumption were determined weekly (first year). Mortality was
assessed at 18 months and 2 years. Histopathological examinations were performed on the lung,
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heart, liver, spleen, pancreas, stomach, small intestine, kidney, adrenal, testis, colon, bone marrow, leg
bones, leg muscles, lymph nodes, uterus, ovary, thyroid and parathyroid. There were no adverse
treatment-related effects observed on any of the investigated parameters (Fitzhugh and Nelson, 1947).
CFY rats (4 weeks old, 35 animal/sex per group) were given a commercial diet containing
monosodium L(+)-tartrate at levels of 0, 25 600, 42,240, 60,160 or 76,800 mg/kg diet (equal to 0,
890, 1,620, 2,200 and 3,100 mg monosodium L(+)-tartrate/kg bw per day for males, and equal to 0,
1,190, 2,050, 3,030 and 4,100 mg monosodium L(+)-tartrate/kg bw per day for females) for
104 weeks (Hunter et al., 1977). Urine was collected from five animals/sex from the control group and
the highest dose group during weeks 4, 8, 12, 24, 52, 77 and 103 and analysed for pH, specific
gravity, protein, reducing substances, glucose, ketones, bile pigments, urobilinogen and haemoglobin.
At the same period of time, blood was collected from a total of 15 animals/sex from the control group
and the highest dose group. Packed cell volume, haemoglobin, red cell count, white cell count, mean
corpuscular haemoglobin and mean cell volume was determined in 10 animals/sex, and plasma urea,
plasma glucose, total serum proteins, serum alkaline phosphatase, serum glutamic pyruvic
transaminase and electrolyte levels were determined in five animals/sex. The animals sacrificed at the
end of the study were subjected to a detailed macroscopic examination. The aorta, lungs, thymus,
cervical and mesenteric lymph nodes, pancreas, stomach, caecum, ileum, duodenum, femur, eyes,
urinary bladder, salivary gland, trachea, oesophagus, muscle, skin and seminal vesicles were preserved
and the brain, pituitary, thyroids, spleen, heart, liver, kidneys, adrenals, testes and ovaries were
preserved and weighed. Microscopic examinations were performed on tissues from 15 animals/sex
from the high-dose group and 10 animals/sex from the control group. After 2 years, a dosage-related
reduction of body weight (15–20% as compared to controls) was observed in male and female rats at
the three highest dose levels compared to controls. According to the authors, this may be partially due
to the slightly reduced food intake (at most 8%), but the Panel noted that the presence of up to 8%
tartaric acid in the diet may have resulted in a nutritional imbalance. There were no treatment-related
adverse effects observed in the urinary, haematological or clinical chemistry parameters, or in the
ophthalmic examinations. Statistically significant relative organ weight changes included: brain, heart,
liver, kidney, uterus and gonad. These increased relative organ weights were mainly due to decreased
body weights. Therefore, the Panel considered these increased relative organ weights not of
toxicological significance. Histopathological examination did not reveal a difference between treated
animals and controls. The Panel considered that monosodium L(+)-tartrate was not carcinogenic and
identified an NOAEL of 3,100 mg monosodium tartrate/kg bw per day, the highest dose tested.
Overall, from the two available toxicity studies in rats, the Panel considered that monosodium L+
tartrate was not carcinogenic and identified an NOAEL of 3,100 mg monosodium tartrate/kg bw per
day, the highest dose tested.




In all studies performed by the Food and Drug Res. Lab. (FDRL, 1973 (Documentation provided to
EFSA No. 5)) with tartaric acid (stereoisomeric form not specified) described below, body weights were
recorded at regular intervals during gestation and all animals were observed daily for appearance and
behaviour. To test the methodology and the sensitivity of the laboratory animals, positive controls were
tested. All dams were subjected to caesarean section, and the numbers of implantation sites,
resorption sites, live and dead fetuses and body weights of live fetuses were recorded. All fetuses were
examined grossly for sex distribution and for external abnormalities (one-third detailed visceral
examination and two-third stained and examined for skeletal defects).
Mice
Groups of 20-–22 pregnant CD-1 mice received on gestation day (GD) 6 to 15 dose levels of 0,
2.74, 12.7, 59.1 or 274 mg tartaric acid/kg bw per day by gavage (vehicle was water; dose volume
10 mL/kg bw) (FDRL, 1973 (Documentation provided to EFSA No. 5)). Body weight was determined at
GD 0, 6, 11, 15 and 17. All dams were subjected to Caesarean section at GD 17. No maternal or
developmental toxicity was detected up to 274 mg tartaric acid/kg bw per day.
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Rats
Groups of 19–24 pregnant Wistar rats received on GD 6 to 15 dose levels of 0, 1.81, 8.41, 39.1 or
181 mg tartaric acid/kg bw per day by gavage (vehicle was water; dose volume 1 mL/kg bw) (FDRL,
1973 (Documentation provided to EFSA No. 5)). Body weight was determined at GD 0, 6, 11, 15 and
20. A Caesarean section was carried out on GD 20. The fetal body weight was increased by 11–16% in
all treated groups. At fetal examination of the skeletons, the number of fetuses and litters with wavy
ribs was increased in all groups dosed with tartaric acid. The Panel considered the effects on wavy ribs
not as adverse as there was no dose relationship and normally wavy ribs are associated with lower
fetal weights and not as in this study with higher fetal weights. Furthermore, no treatment-related
maternal or developmental toxicity was detected up to 181 mg tartaric acid/kg bw per day. No
statistical analysis of the data was performed.
Hamsters
Groups of 20–23 pregnant golden hamsters received dose levels of 0, 2.25, 10.45, 48.35 or 225 mg
tartaric acid/kg bw per day by gavage (vehicle was water; dose volume 1 mL/kg bw) from GD 6 to 10
(FDRL, 1973). Body weight was determined at GD 0, 8, 10 and 14. On GD 14, a Caesarean section
was carried out. There was no evidence for maternal or developmental toxicity up to 225 mg tartaric
acid/kg bw per day.
Rabbits
Groups of 15–19 inseminated Dutch-belted rabbits (10–11 pregnant does/group) received via
gavage dose levels of 0, 2.15, 10, 46.4 or 215 mg tartaric acid/kg bw per day by gavage (vehicle was
water; dose volume 1 mL/kg bw) from GD 6 to 18 (FDRL, 1973 (Documentation provided to EFSA No.
5)). Body weight was determined at GD 0, 6, 12, 18 and 29. On GD 29, a Caesarean section was
performed. Fetal weight of the groups dosed with tartaric acid was decreased with approx. 7, 9, 9 and
15% in the 2.15, 10, 46.4 or 215 mg tartaric acid/kg bw per day groups compared to the control
group. Furthermore, there was no evidence for maternal or developmental toxicity up to 215 mg
tartaric acid/kg bw per day. No statistical analysis was performed.
Overall, no maternal or developmental effects were reported in mice, rats, hamsters or rabbits
administered tartaric acid during organogenesis at the highest dose tested (mice: 274 mg/kg bw per
day, rats: 181 mg/kg bw per day, hamsters: 225 mg/kg bw per day or rabbits: 215 mg/kg bw per day
for 13 days). No studies for reproductive toxicity were available.
3.5.7. Hypersensitivity, allergenicity and food intolerance
No data were available.
3.5.8. Other studies
Sodium tartrate has been used as a laxative (Gold and Zahm, 1943). Forty-three patients with pre-
existing constipation were given for 379 days a daily dose of 10 g of sodium tartrate. In this study,
1.6% of the patients experienced nausea and/or vomiting and 2.1% had abdominal cramps.
Potassium sodium tartrate (Rochelle salt) has been used medically as an osmotic laxative in doses of
10 g (corresponding to 143 mg potassium sodium tartrate/kg bw per day for an adult (70 kg)) (Fingl,
1965). This therapeutic use, which corresponds to the bolus intake of a large dose of potassium sodium
tartrate in drinking water, was not applicable to the assessment of this tartrate salt as a food additive.
A fatal case was reported of a man having accidentally ingested an aqueous solution containing
tartaric acid. (approximately 30 g) (Robertson and Lonnell, 1968). Due to the uncertainties in this
report (e.g. composition of the aqueous solution, exact dose ingested, pre-existing health status of the
man,. . .) together with the bolus ingestion of the solution, the Panel considered that this observation
was not relevant for the assessment of tartaric acid as a food additive.
Two subjects (A and B, gender not specified) were given sodium L(+)-tartrate in three oral doses of
a total of 1.5 mmol/kg per day (corresponding to 285 mg/kg bw per day) for 2 (Subject A) or 4
(Subject B) days (Chadwick et al., 1978). Changes in plasma total CO2 was measured in subject B and
pH, protein and creatinine were measured in urine from both subjects. Urine pH from subject A and B
was 5.8 and 7.69 before and at the end of the dosing, respectively. There was no proteinuria, and
creatinine clearance did not change after tartrate administration. A slight purgative effect was
observed in both subjects and the urine output from subject B rose to 3,500 mL/day during the
dosing. The total CO2 content of venous plasma from subject B was 31.4 mmol/L on the last day
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before the dosing; 34 mmol/L on the last day of dosing and 30.3 mmol/L on day 4 after the dosing
showing, according to the authors ‘that the alkaline urine caused by tartrate was not a consequence of
renal damage impairing the mechanism of urinary acidification, but a normal renal response to the
mild systemic alkalosis caused by the conversion of ingested sodium tartrate into bicarbonate’
Potassium tartrate was given in the form of Cal-K® tablets (Somapharm, Lachine, Que.) to 20
healthy volunteers (8 men and 12 women, mean weight 64.6  10.6 kg) for 2 days (Whiting et al.,
1991). The daily dose of potassium tartrate was 34 mmol (corresponding to 85–119 mg/kg bw per
day). Urine was collected throughout the study. The urinary creatinine excretion did not vary
significantly for any subject during the study and no adverse side-effects were reported.
Naqvi (2017) reported four cases of acute tubular necrosis in patients who had consumed ‘large
amounts of tartaric acid’ without specifying the form of tartaric acid (L(+)-, D(-)-, or DL-). In addition,
the Panel noted that according to the authors: ‘most of patients cannot describe the amount of
substances taken’. Therefore, the Panel could not consider this report in the evaluation of tartaric acid
and its salts used as food additives (E 334-337).
Using a data-driven computational in silico approach to evaluate the gut microbial metabolites that
may affect (i.e. promote or protect) ColoRectal Cancer (CRC), Wang et al. (2018) reported that tartaric
acid was associated with a number of genes and suggested that through its fermentation products
(e.g. SCFAs), it could play significant roles by participating in many biological functions including
cytokines and inflammatory response during the development of CRC. For instance, the SCFA butyrate
has a role in the suppression of inflammation and colorectal cancer. The Panel noted that these
hypotheses deserved further investigation.
Several case reports and one case series were published on patients diagnosed with kidney or
bladder stones consisting of calcium tartrate tetrahydrate (Kleinguetl et al., 2017, 2019). According to
Kleinguetl et al. (2019) who identified the cases from a search in the Mayo Clinic patient databank, the
incidence of calcium tartrate tetrahydrate stone formation is extremely rare (around 0.007%; 7 cases
of calcium tartrate tetrahydrate stones in 100,000 stone patients). Three of the patients diagnosed
with calcium tartrate tetrahydrate stones declared they consumed daily for a long period of time, large
amounts of vitamin and amino acid supplement energy drink/powders containing, among several other
components, ‘L-carnitine-L-tartrate’ and ‘choline bitartrate’. According to Klurfeld (2002), kidney and
bladder stones and renal failure observed in rats was associated with the consumption of choline
bitartrate in rodent diet due to the substitution of L(+)-tartrate by DL-tartrate that was used for the
production of choline bitartrate as an ingredient or due to a toxic contaminant at trace levels
introduced into the product at some step in the process, possibly during synthesis of DL-tartaric acid
(Klurfeld, 2002). The Panel noted that the formation of kidney stones in rats was also associated with
the consumption of racemic choline bitartrate (Kankesan et al., 2003; Newland et al., 2005). The
Panel also noted that Le Bail et al. (2009) demonstrated that racemic tartrate was a constituent of the
stones observed in rats. The Panel considered that the observations from these studies underline the
difference in toxicity between the D(-)- and L(+)- form of tartaric acid.
3.6. Discussion
L(+)-tartaric acid (E 334), sodium tartrate (E 335 (i)), disodium tartrate (E 335 (ii)), potassium
tartrate (E 336 (i)), dipotassium tartrate (E 336 (ii)), potassium sodium tartrate (E 337) were
previously evaluated by JECFA several times, the latest in 1977 (JECFA, 1962, 1964, 1965, 1974a,b,
1975, 1977, 1978, 1983) and the SCF in 1990 (SCF, 1991b). Both committees established a group ADI
of 30 mg/kg bw per day for L(+)-tartaric acid and its potassium and sodium salts.
Information on the manufacturing process of L(+)-tartaric acid using immobilised cells of the
bacteria Rhodococcus ruber strain CM001 or Rhodococcus sp strain USA-AN012 was submitted.
Rhodococcus ruber has not been reported to be pathogenic to humans. Rhodococcus sp strain
USA-AN012 shows resistance to gentamycin for which a genetic basis has not been identified. In
addition, the strain carries a gene which has been involved in resistance to vancomycin, although the
strain was sensitive to this antimicrobial. Since no viable cells from Rhodococcus sp USA-AN012
remained in the final product, and the manufacturing conditions were shown able to fully degrade
DNA, the use of immobilised cells of the bacteria Rhodococcus ruber strain CM001 or Rhodococcus sp
strain USA-AN012 was not considered to pose a safety concern.
The Panel considered that the manufacturing process of L(+)-tartaric acid from chemical/
microbiological production may result in impurities different from those that may be present in L(+)-
tartaric acid as a by-product of wine production. The Panel, therefore, considered that separate
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specifications would be needed for L(+)-tartaric acid from chemical/microbiological production using
Rhodococcus ruber strain CM001 or Rhodococcus sp strain USA-AN012.
The specifications for L(+)-tartaric acid from chemical/microbiological production should include
parameters relevant for these specific manufacturing processes:
• proper definition to describe the manufacturing process and the two bacteria, Rhodococcus
ruber strain CM001 or Rhodococcus sp strain USA-AN012, assessed in the current evaluation.
• The absence of DNA in the final product demonstrated (EFSA CEP, 2019).
• The absence of viable cells in the final product demonstrated, using an analytical method
(testing at least 1 g of product) (EFSA CEP, 2019).
• maximum limits for heavy metals (e.g. vanadium, molybdenum and tungsten) resulting from
the use of any catalyst.
The metabolism of L(+)-tartaric acid and its potassium sodium salt was shown to be species-
dependent. In rats, after oral administration, up to 81% of labelled tartrate was absorbed (Underhill
et al., 1931a; Chadwick et al., 1978; Gry and Larsen, 1978). In rats, L(+) and D(-)-tartrate were excreted
differently in urine after gavage, the L(+)-form being more efficiently excreted than the D(-)-form (Gry and
Larsen, 1978). Up to 10% of labelled parenteral tartrate was expired as CO2 within 6 h and 63% was
found in the urine over 24 h, which indicated significant metabolism by tissues (Chadwick et al., 1978).
High rate of renal excretion (up to 60% within 12 h) was reported in dogs receiving tartaric acid (Sourkes
and Koppanyi, 1950). Underhill et al. (1931a) found that after parenteral injection of tartrate, recovery
ranged from 70% in rabbits, dogs and rats to almost 100% in guinea pigs. Therefore, tissue metabolism
could not be excluded in these species; however, it played a minor role in disposal of tartrate.
In humans, only 12% of tartrate administered orally appeared in the urine; as this was unrelated to
dose absorption was likely passive (Chadwick et al., 1978). The difference in urinary excretion after an oral
dose (12%) or an intravenous dose (66%) suggested that only a fraction of the oral dose was systemically
available (approximately 18% according to Chadwick et al., 1978). Finkle (1933) found that 91% of an
intramuscular dose of unlabelled tartrate was recovered in the urine, which according to the authors,
indicated that the human body cannot metabolise tartrate. It must be noted, however, that in the
intramuscular part of the study, D-tartrate was most probably used because the author described
D-tartrate in the oral part of the study. After an intravenous injection of 14C-L-tartrate, Chadwick et al.
(1978) reported that 66% of the radioactivity was excreted in the urine in 22 h, and that 18%was excreted
as 14CO2 over 8 h. The concentration of
14CO2 in expired air peaked after 1 h and contained 7% of the dose
suggesting, a rapid metabolism by tissue enzymes. The Panel considered that the different recoveries of 91
and 66% may be due to the different stereospecific forms. However, these recoveries are not directly
comparable because radioactivity was measured in one study while unlabelled tartrate was analysed in the
other study. Tartrate was fermented by colonic bacteria, with L(+)-tartrate being metabolised faster than D
(-)-tartrate (Chadwick et al., 1978). Spiller et al. (2003) reported that tartaric acid/tartrate were fermented
by colonic bacteria to SCFAs, which then can be absorbed in the colon (Dawson et al., 1964).
It is necessary to consider whether the hazard could only be due to the parent compounds. In this
respect, the metabolic products originating from the metabolism of the unabsorbed tartaric acid/tartrate
by the microbiome in the lower part of the gastrointestinal tract have to be evaluated. In the study by
Chadwick et al. (1978), the authors confirmed that tartrate is not metabolised to oxalate, a potential
metabolite with toxic properties for the kidney; most of the 14C- label was recovered as 14CO2. Hence,
from the ADME data, it can be concluded that the metabolites would not cause potential side effects.
An LD10 value for disodium tartrate above 4,000 mg/kg bw in mice was indicative of a low oral
toxicity of tartrate in this species (Locke et al., 1942). Acute renal toxicity was seen in rabbits and dogs
after a single oral dose of tartaric acid or Rochelle salt (potassium sodium tartrate) from 26.6 and
600 mg/kg bw (expressed as tartaric acid), respectively (Underhill et al., 1931a).
No adverse effects were observed in rats given 2,730 monosodium L-tartrate/kg bw per day. In the
same study, DL-tartaric acid was shown to cause kidney effects. Furthermore, in a 90-day study in rats,
an NOAEL of 60 mg/kg bw per day was identified for monopotassium DL-tartrate, based on kidney
histological alterations (obstructive nephropathy) reported at higher doses. In rabbits given 550 mg
monosodium tartrate/kg bw per day acid (stereoisomeric composition not specified), no adverse effects
were observed. Advanced tubular degeneration of the kidneys and increased blood NPN, creatinine and
albumin were observed in one out of the four dogs given 990 mg tartaric acid/kg bw per day
(stereoisomeric composition not specified), the only dose tested. The Panel considered that the renal
effects reported with tartrates were most likely due to the presence of the D(-)-form of tartaric acid only.
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L(+)-tartaric acid, monosodium, monopotassium and potassium sodium tartrates did not show a
mutagenic potential in several strains of Salmonella typhimurium and Escherichia coli. The Panel noted
that all studies had shortcomings, however, considering the available data in a weight of evidence
approach, there is no concern with respect to a potential for induction of gene mutations. Concerning
structural and numerical chromosome aberrations, there are no reliable in vitro data available and one
in vivo study was of limited reliability. However, based on these data, there was no indication for
structural or numerical chromosomal aberrations. Taking also into account that tartaric acid and
tartrates do not have a structural alert for genotoxicity, the Panel considered that, overall, there was
no concern for genotoxicity for tartaric acid and its sodium and potassium salts.
A dosage-related reduction of body weight and higher relative weights for a number of organs were
reported for rats fed monosodium tartrate at doses equal to or above 1,620 and 2,050 mg/kg bw per
day for males and females, respectively, for 2 years (Hunter et al., 1977). These increased relative
organ weights were mainly due to decreased body weights. The Panel considered that the decrease in
body weights was due to a nutritional imbalance likely due to palatability effect, and therefore,
considered these increased relative organ weights not of toxicological significance. Histopathological
examination did not reveal a difference between treated animals and controls. From the available
chronic and carcinogenicity studies (Fitzhugh and Nelson, 1947; Hunter et al., 1977), the
Panel considered that monosodium L(+)-tartrate was not carcinogenic and identified an NOAEL of
3,100 mg monosodium tartrate/kg bw per day, the highest dose tested. The Panel noted that the
current ADI of 30 mg/kg bw per day, expressed as tartaric acid and established by the SCF, was
derived from this study which was performed with monosodium tartrate.
No maternal or developmental effects were reported at the highest dose tested (mice: 274 mg/kg
bw per day, rats: 181 mg/kg bw per day, hamsters: 225 mg/kg bw per day or rabbits: 215 mg/kg bw
per day for 13 days). The Panel noted that the doses used in these studies were low; the authors of the
report did not explain why they selected these doses; it could be due to the low pH of tartaric acid,
which limited the possible amount of this acid to be administered by gavage; it was also noted that in
the only toxicity study where tartaric acid and not one of its salt was administered to the animals, the
highest dose added to the feed corresponded to only 600 mg/kg bw per day. The Panel considered that
there was no indication of maternal or developmental effects from these studies and that owing to the
low doses used, the NOAELs that could be identified were not relevant for the derivation of an ADI.
No studies for reproductive toxicity were available, however, no histopathological findings were
reported in testes, ovaries and uterus in various studies: Inoue et al. (2015) rats up to 480 mg tartaric
acid/kg bw per day for 90 days, Fitzhugh and Nelson (1947) rats up to 600 mg/kg bw per day
2 years, Hunter et al. (1977) rats up to 2400 mg/ kg bw per day for 2 years. In addition, in the
CMBEC report (2004), in mice given up to 2,150 mg L(+) tartaric acid/kg bw per day by gavage for
5 days, no statistically significant differences in the frequency of ‘cell aberration’ in primary
spermatocytes were observed in the treated groups compared to the negative control groups.
In humans, sodium tartrate has been used as a laxative; in the Gold and Zahm study (1943), 43
patients with pre-existing constipation were given doses of 10 g of sodium tartrate (daily or once or
twice a week, number of doses varying from 1 to 100) and 1.6% of the patients experienced nausea
and/or vomiting and 2.1% had abdominal cramps. The Panel noted that sodium tartrate was given as
a bolus dose in water for a prolonged period of time and that the symptoms were poorly described. In
addition, according to the authors, the study population had chronic constipation and comprised
‘patients with heart disease among other health problems’. Accordingly, the Panel considered this
observation not relevant for the risk assessment of tartaric acid/tartrates as food additives. Naqvi
(2017) reported four cases of acute tubular necrosis in patients who had consumed ‘large amounts of
tartaric acid’; the amount and form of tartaric acid absorbed were not specified. The Panel noted that
adverse effects of tartrate or tartaric acid were observed only after ingestion of high bolus doses of
tartaric acid in water, and the form of tartaric acid consumed was not indicated
Derivation of an ADI using a chemical-specific uncertainty factor for tartaric acid-
tartrates
A group ADI of 30 mg/kg bw per day was established by JECFA (1974a) and later endorsed by the
SCF (SCF, 1991b). This ADI was derived from an NOAEL of 3,000 mg monosodium tartrate/kg bw per
day, the highest dose tested in a chronic toxicity study in rats (Hunter et al., 1977), and applying an
uncertainty factor of 100.
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The Panel considered whether this uncertainty factor would be appropriate given the fact that the
absorption of tartaric acid/tartrate is greater in rats than humans. Whereas in the rat the systemic
availability was 81%, the systemic availability in humans amounted to 18% (Chadwick et al., 1978).
The Panel decided that the available data on systemic availability were robust enough to derive a
chemical-specific uncertainty factor instead of the usual default uncertainty factor of 100.
The default uncertainty factor of 100 is composed of a factor of 10 accounting for the difference
between animal and human and a second factor of 10 accounting for the variability in the human
population. The two factors consist of two components, one component describing the toxicokinetic
difference and variability, respectively, and the other component describing the toxicodynamic difference
and variability, respectively. For the toxicokinetic component of the interspecies factor a value of 4 is used
when extrapolation is made from the rat to the human (EFSA Scientific Committee, 2012). This factor of 4
is based on allometric scaling from rat to humans. The remaining factor of 2.5 is attributed to the
toxicodynamic interspecies difference. The human factor of 10 accounting for the variability in the human
population is subdivided into two factors of 3.2 accounting for toxicokinetic and toxicodynamic variability.
In 2004, the IPCS/WHO proposed a framework indicating how chemical-specific toxicokinetic and/or
toxicodynamic data can be used to replace the default factors or its subfactors (WHO, 2004).
When considering the systemic toxicity of the parent compounds tartaric acid/tartrates, toxicity is
related to the amount, which is given as the internal dose. Accordingly, the external (administrated)
dose can be adjusted to the internal dose by taking into account how much is absorbed and
systemically available after oral administration. In humans, 18% of the dose is systemically available
whereas in rats the figure is 81%. Furthermore, it is to be noted that the rate of metabolism is similar
between rats and humans as measured by the rate of expired CO2. The usual default value for the
toxicokinetic differences between rats and humans is 4 assuming that in general the internal human
exposure is four times higher than in the rat with the same external dose. In case of tartrate, the
situation is reverse; in humans, the internal exposure is 22% of that in rats. Hence, when considering
the different absorption in rats and humans, together with the similar rate of metabolism, the
interspecies toxicokinetic factor may be reduced to 0.22 instead of 4.
Multiplying this interspecies toxicokinetic factor of 0.22 by the default toxicodynamic factor of 2.5
would result in an interspecies uncertainty factor of 0.55. As a conservative approach, the
Panel decided to use an interspecies factor of 1. For the intraspecies factor, the Panel had no
information allowing possible modification of the default factor and, therefore, the default factor of 10
was used. Accordingly, the resulting overall uncertainty factor would be 10 (1 9 10).
Applying the uncertainty factor of 10 to the reference point of 3,100 mg sodium tartrate/kg bw per
day, approximately 2,440 mg tartaric acid/kg bw per day, will result in a group ADI for tartaric acid
and tartrates (E 334-337 and E 354) of 240 mg/kg bw per day expressed as tartaric acid.
The difference between the ADI established by the SCF and the one derived in this opinion is due
to the application of a chemical-specific interspecies uncertainty factor instead of the default
uncertainty factor used in previous evaluations.
Dietary exposure to tartaric acid and tartrates (E 334-337 and E 354) from their use as food
additives was calculated according to different exposure scenarios based on MPLs and the reported
use levels, as described in Section 3.4. According to Annex II to Regulation N°1333/2008, tartaric acid
and tartrates (E 334-337 and E 354) are authorised in 81 food categories of which 66 under Group I
food additives.
For tartaric acid and tartrates (E 334-337 and E 354), use levels were reported by industry for 17
food categories. Based on the information of the Mintel’s GNPD, approximately 82% of the food
products labelled with tartaric acid and tartrates (E 334-337 and E 354) in this database were
considered in the exposure assessment. Based on the observations that
• 100% of the foods belonging to a food category included in the assessment were assumed to
contain tartaric acid, whereas the average percentage was 1% according to Mintel’s GNPD;
• the possible degradation of tartaric acid at high temperatures was not addressed in the
assessment,
the Panel considered that the exposure to tartaric acid and tartrates (E 334-337 and E 354) from their
use as food additives according to Annex II to Regulation (EC) No 1333/2008 was overestimated in all
exposure scenarios (Section 3.4.1).
Tartaric acid and tartrates (E 334-337 and E 354) are used as ‘acidity regulator’ and are therefore
not expected to change the organoleptic properties of the final food at the concentration used as a
food additive. For this reason, the Panel considered the non-brand-loyal scenario covering the general
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population as the most appropriate scenario for risk characterisation. Dietary exposure to tartaric acid
and tartrates (E 334-337 and E 354) according to this exposure scenario was up to 91 mg/kg bw per
day at the mean level and 174 mg/kg bw per day at the high (P95) level in infants.
A consumer’s only scenario including the exposure to tartaric acid-tartrates (E 334-337 and E 354)
through the intake of food supplements was also calculated. High (P95) level exposure was up to
93 mg/kg bw per day in children.
Since tartaric acid also occurs naturally in food, the Panel calculated the intake of tartaric acid from
natural sources (non-processed fruits and vegetables (corresponding to FC 04.1) and wine), based on
the limited available information reported in the literature. This exposure was lower than the calculated
exposure from the use of tartaric acid-tartrates as food additives, maximally 26 mg/kg bw per day in the
elderly.
Exposure to tartaric acid in addition to via natural occurrence, can also occur by release from other
food additives, including tartaric acid esters of mono- and diglycerides of fatty acids (E 472d), mono-
and diacetyl tartaric acid esters of mono- and diglycerides of fatty acids (E 472e), mixed acetic and
tartaric acid esters of mono- and diglycerides of fatty acids (E 472f), metatartaric acid (E 353) and
stearyl tartrate (E 483). The Panel, therefore, also calculated the potential exposure to tartaric acid
from these sources and combined it with the exposure to tartaric acid due to the use of tartaric acid
and tartrates (E 334-337 and E 354). The non-brand-loyal exposure scenario was considered for the
exposure due to the use of food additives. The exposure to tartaric acid from stearyl tartrate (E 483)
was not included in this assessment, as no reported use levels were available for this food additive.
The highest P95 level of exposure was estimated for toddlers at 285 mg/kg bw per day.
The Panel noted that the exposure to tartaric acid and tartrates (E 334-337 and E 354) from their
use according the Annex III (Parts 2, 3, 4 and 5A) was not considered in the exposure assessment.
The Panel also noted that the refined exposure estimates are based on reported levels of use of
tartaric acid and tartrates (E 334-337 and E 354). If actual practice changes, these refined estimates
may no longer be representative and should be updated.
Overall, the Panel considered that:
• Only L(+)-tartaric acid and its sodium, potassium and calcium salts are authorised as food
additives in the EU and, therefore, the only subject of this assessment.
• L(+)-tartaric acid is naturally present in many fruits (e.g. grapes, apples).
• In many biological studies, the stereoisomeric form of the tartaric acid/tartrate salt used was
not specified.
• In humans, salts of tartaric acid although not digested in the small intestine are fermented in
the colon to SCFAs, and once absorbed, these SCFAs follow their natural degradation pathway.
• No toxic effects were observed in toxicological studies in which the L(+)-form was tested. In
contrast, nephrotoxicity was reported in studies in which the DL-form has been tested and,
therefore, it can be associated with the D(-)-form.
• There was no indication for a genotoxic potential of tartaric acid and its sodium and potassium
salts.
• There was no indication for carcinogenicity of monosodium L(+)-tartrate at the highest dose
tested (3,100 mg /kg bw per day).
• The available studies for maternal or developmental toxicity did not report any relevant effects,
no studies for reproductive toxicity were available and no effects on reproductive organs were
observed in the chronic toxicity study.
• A total uncertainty factor of 10 was derived by applying a total interspecies uncertainty factor
of 1 instead of 10, based on data showing lower internal exposure to tartaric acid in humans
compared to rats.
• Applying the total uncertainty factor of 10 to the reference point of 3,100 mg sodium tartrate/
kg bw per day, that is approximately 2,440 mg tartaric acid/kg bw per day, will result in a
group ADI for tartaric acid and tartrates (E 334-337 and E 354) of 240 mg/kg bw per day
expressed as tartaric acid.
• In the various populations, exposure estimates to tartaric acid and tartrates (E 334-337 and
E 354) in the non-brand loyal exposure scenario ranged from less than 1 to 91 mg/kg bw per
day at the mean and from 2 to 174 mg/kg bw per day at the 95th percentile.
• For calcium tartrate (E 354), no use was reported and only one food was reported to be
labelled with this food additive in Mintel’s GNPD.
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• In the various populations, the combined exposure estimates to tartaric acid from the use of
tartaric acid and tartrates (E 334-337 and E 354) and other relevant food additives (E472d,
E472f, E472e, E 354), using the non-brand loyal exposure scenario, and natural occurrence
ranged from 2 to 130 mg/kg bw per day at the mean and from 8 to 285 mg/kg bw per day at
the 95th percentile.
• The calculated exposure to tartaric acid and tartrates (E 334-337 and E 354) from their use as
food additives according to Annex II to Regulation N°1333/2008, as well as the calculated
exposure to tartaric acid from the use of the different relevant food additives (E472d,e,f and
E 353) and natural sources are overestimates.
4. Conclusions
The Panel concluded that the data on systemic availability were robust enough to derive a
chemical-specific uncertainty factor instead of the usual default uncertainty factor of 100. Therefore, a
total uncertainty factor of 10 was derived by applying a total interspecies uncertainty factor of 1
instead of 10, based on data showing lower internal exposure in humans compared to rats.
The Panel established a group ADI for L(+)-tartaric acid and tartrates (E 334-337 and E 354) of
240 mg/kg bw per day, expressed as tartaric acid, by applying the total uncertainty factor of 10 to the
reference point of 3,100 mg sodium tartrate/kg bw per day (the highest dose tested), that is
approximately 2,440 mg tartaric acid/kg bw per day. Accordingly, the current ADI of 30 mg/kg bw per
day is withdrawn.
The group ADI of 240 mg/kg bw per day, expressed as tartaric acid, does not apply to D(-)-,DL- or
meso-tartrate.
The exposure estimates for L(+)-tartaric acid and tartrates (E 334-337 and E 354) for the different
population groups for the refined non-brand-loyal exposure scenario, which was considered by the
Panel as the most relevant scenario, did not exceed the group ADI of 240 mg/kg bw per day,
expressed as tartaric acid.
Considering additionally the exposure to tartaric acid from the use of tartaric acid esters of mono-
and diglycerides of fatty acids (E 472d), mono- and diacetyl tartaric acid esters of mono- and
diglycerides of fatty acids (E 472e), mixed acetic and tartaric acid esters of mono- and diglycerides of
fatty acids (E 472f) and metatartaric acid (E 353) and natural occurrence, the P95 level of exposure in
toddlers would exceed the group ADI. However, the Panel did not consider this exceedance to indicate
a possible health concern, due to the overestimation of the exposure.
Recommendations
The Panel recommended that the European Commission considers:
• Revising the authorisation of DL-tartaric acid as a processing aid (stabilising agent) in wine,
according to Commission Regulation (EC) No 934/2019, in the light of the observed
nephrotoxic effect of DL-tartaric acid.
• Establishing separate specifications for L(+)-tartaric acid from chemical/microbiological
production in Commission Regulation (EU) No 231/2012.
• Revising the EU specifications for monosodium tartrate (E 335(i)), disodium tartrate (E 335(ii),
monopotassium tartrate (E 336(i)), dipotassium tartrate (E 336(ii)) and potassium sodium
tartrate (E 337) in order to introduce a provision for specific rotation to ensure the exclusive
use of the authorised L(+)-stereoisomer in these food additives.
• Revising the EU specifications for disodium tartrate (E 335(ii) in order to correct the mistake
where this compound is indicated as ‘insoluble’ whereas it is soluble.
• Revising the EU specifications for sodium tartrate (E 335(i)) in order to correct the molecular
weight to ‘190.08 g/mol’.
• Harmonising the name for the food additive E 337 in Commission Regulation (EU) No 231/
2012 and in the Regulation (EC) No 1333/2008 on food additives. Both Regulations should use
the name potassium sodium tartrate for E 337.
• Setting lower maximum limits for toxic elements (lead, mercury and arsenic) in the EU
specification for L(+)-tartaric acid (E 334), monosodium tartrate (E 335 (i)), disodium tartrate
(E 335 (ii)), monopotassium tartrate (E 336 (i)), dipotassium tartrate (E 336 (ii)), potassium
sodium tartrate (E 337) and calcium tartrate (E 354) in order to ensure that their use as food
additives will not be a significant source of exposure to these toxic elements in food.
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and/or concentration data in food and beverages intended for human consumption (2016).
Submitted to EFSA on 1 February 2017.
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Abbreviations
ADME absorption, distribution, metabolism, excretion
ADI acceptable daily intake
AESGP Association of the European Self-Medication Industry
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ANS EFSA Panel on Food Additives and Nutrient Sources added to Food
bw body weight
CAS Chemical Abstracts Service
CONTAM EFSA Panel on Contaminants
ECHA European Chemical Agency
EDA European Dairy Association
ESA European Snacks Association/SNACMA
EINECS European Inventory of Existing Commercial Chemical Substances
FAF EFSA Panel on Food Additives and Flavourings
FC food category
FCS food categorisation system
FDE Food Drink Europe
FIA flow injection analysis
FSE Food Supplements Europe
FTIR Fourier Transform IR
HIPP HiPP-Werk Georg Hipp OHG
HPLC high-performance liquid chromatography
ICGA International Chewing Gum Association
JECFA Joint FAO/WHO Expert Committee on Food Additives
LD50 lethal dose, median
LOD limit of detection
LOQ limit of quantification
MPL maximum permitted level
NOAEL no observed adverse effect level
OECD Organisation for Economic Co-operation and Development
QS quantum satis
REACH Registration, Evaluation, Authorisation and Restriction of Chemicals
SCF Scientific Committee on Food
SNE Specialised Nutrition Europe
TemaNord is a publishing series for results of the often research-based work that working
groups or projects under Nordic Council of Ministers have put in motion
UPLC-Q/TOF-MS ultra-performance liquid chromatography quadrupole time-of-flight mass
spectrometry
WHO World Health Organization
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Appendix A – Summary of the reported use levels (mg/kg or mg/L as
appropriate) of tartaric acid and tartrates (E 334-337 and E 354) provided
by industry
Appendix B – Summary of analytical results (mg/kg ormg/L as appropriate) of
tartaric acid and tartrates (E 334-337and E 354) provided byMember States
Appendix C –
1. Number and percentage of food products labelled with tartaric acid and tartrates
(E 334-337 and E 354) out of the total number of food products present in the Mintel
GNPD per food subcategory between 2014 and 2019
2. Number of food products labelled with two food additives: tartaric acid and tartrates
(E 334-337 and E 354) out of the total number of food products present in the Mintel
GNPD per food subcategory between 2014 and 2019
Appendix D – Concentration levels of tartaric acid and tartrates (E 334-337
and E 354) used in the exposure assessment scenarios (mg/kg or mL/kg
as appropriate)
Appendix E – Summary of total estimated exposure to tartaric acid and
tartrates (E 334-337 and E 354) from their use as food additives for the
maximum level exposure scenario and the refined exposure assessment
scenarios per population group and survey: mean and 95th percentile
(mg/kg bw per day)
Appendix F – Main food categories contributing to exposure to tartaric acid
and tartrates (E 334-337 and E 354) using the maximum level exposure
assessment scenario and the refined exposure assessment scenarios
(> 5% to the total mean exposure)
Appendix G – Summary of total estimated exposure to tartaric acid and
tartrates (E 334-337 and E 354) from their use as food additives for the
food supplements consumers only exposure assessment scenarios per
population group and survey: mean and 95th percentile (mg/kg bw per
day)
Appendix H – Summary of tartaric acid levels (mg/kg or mg/L as
appropriate) in food as found in literature
Appendix I – Summary of total estimated exposure to tartaric acid from its
natural occurrence in the diet, per population group and survey: mean and
95th percentile (mg tartaric acid/kg bw per day)
Appendix J – Concentration levels used in the exposure assessment
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Appendix K – Summary of total estimated exposure to tartaric acid from
their use as food additives for the maximum level exposure scenario and
the refined exposure assessment scenarios per population group and
survey: mean and 95th percentile (mg/kg bw per day)
Appendix L – Main food categories contributing to exposure to tartaric acid
using the maximum level exposure assessment scenario and the refined
exposure assessment scenarios (> 5% to the total mean exposure)
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